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ABSTRACT OF DISSERTATION

POLYAMINE MODULATION IN ALCOHOLISM: EXAMINATION USING A
NOVEL SCREENING PROCEDURE DESIGNED TO PREDICT ANTI-RELAPSE
AND NEUROPROTECTIVE EFFICACY
Alcohol dependence is a major public health concern. Despite the FDA’s approval
of multiple anti-relapse drugs, relapse rates remain unacceptably high. Furthermore,
cognitive deficits among chronic drinkers are evident and are suggested to contribute to
relapse risk. Current evidence suggests that several critical features of alcoholism and
alcohol-associated neurodegeneration are mechanistically linked to glutamatergic actions;
specifically, they appear positively affected by glutamatergic inhibition, particularly
inhibition via polyamine modulation of a subpopulation of n-methyl-d-aspartate
receptors. The current project was designed to evaluate the performance of two putative
polyamine modulators (JR-220 and CP-101,606) in a variety of screens designed to
identify the potential to reduce withdrawal severity, neurotoxicity and relapse risk.
Screens included a complex organotypic screen designed to assess neuroprotective
potential (Experiment 1), a simple behavioral screen designed to assess withdrawal
severity (Experiment 2) as well as several more complex behavioral screens designed to
examine cue-conditioning during withdrawal (Experiment 3), relapse behavior
(Experiment 4), stress-associated consumption (Experiment 5) and binge-like
consumption (Experiment 6). An additional open field experiment (Experiment 7) was
conducted in order to address interpretational issues concerning activity in Experiments
2-6. Finally, as a first step in moving beyond simple screening, we expanded our binge
screen to adhere more closely to an established, validated model of binge consumption
(Experiment 8). While some interpretational issues were noted, taken together, the results
from these experiments provide strong evidence for both drugs as potential
pharmacotherapies for alcoholism and further implicate polyamines and NR2B subunits
as critical mechanisms in ETOH consumption and withdrawal.
KEYWORDS: Alcohol, Polyamines, Excitotoxicity, Relapse, NMDAr, Drug
Development
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Chapter 1. Introduction
Alcohol dependence is a major public health concern, with an estimated annual
economic cost of over $180 billion (Harwood, 2000; NIAAA, 2004; Lupton, Burd &
Harwood, 2004). In the US, alcohol dependence ranks 3rd in preventable mortality
(DHHS, 2000), is estimated to affect approximately 4% of the population (Grant et al.,
2004), and contributes to more than 100,000 deaths, annually (McGinnis & Foege, 1999).

Alcohol dependence, herein referred to as alcoholism, is a chronic, relapsing
disorder with numerous detrimental health consequences. DSM-IV characterization of
dependence includes frequent intoxication, compulsion to consume alcohol, tolerance,
loss of control in limiting consumption despite adverse consequences and emergence of a
negative emotional state during withdrawal (American Psychiatric Association [DSM-IVTR], 2000). The DSM-IV recognizes both alcohol dependence and abuse as alcohol use
disorders (AUDs), however alcohol abuse diagnoses are reserved primarily for
individuals not reaching criteria for dependence, but who drink despite alcohol-related
problems, or drink in dangerous situations (e.g., driving). Alcohol abuse was the most
common problem treated in substance abuse treatment centers from 1994-1999, with 18.2
million people in the US meeting AUD criteria (SAMHSA, 2008).

Ethanol (C2H5OH; ETOH), also referred to as ethyl or grain alcohol, is a small
straight-chain molecule, and the intoxicating component in alcoholic beverages. Evidence
for human ETOH consumption has been noted as far back as the Neolithic period
(McGovern et al., 2004), and its contemporary consumption across cultures is nearly
ubiquitous. Ethanol is considered a central nervous system (CNS) depressant and
psychoactive drug. Dosage is quantified as blood alcohol content (BAC), either as mg/dl,
or as % v/v.
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Due to the aforementioned economic and health concerns, the development and
identification of efficacious treatments for alcoholism remain primary goals in basic
research. The current work is focused on the identification and development of known
and novel compounds, examining their potential efficacy as neuroprotective and antirelapse agents.

1.1 Subjective Effects
ETOH has a wide array of subjective effects, dependent on individual differences,
dose, and expectations (Sher et al., 2005), which can be generally characterized as
anxiolytic, disinhibitive and euphorigenic. Paradoxically, while considered a CNS
depressant, ETOH possesses strong stimulatory properties, particularly at lower doses,
and during the ascending limb of the BAC curve. At lower doses (.02-.05 mg/dl BAC),
ETOH produces feelings of “warmth” and relaxation. Moderate doses (.05-.09 BAC) are
associated with reduced inhibitory control, euphoria and mild psychomotor perturbances.
Higher doses (.1-.19 BAC) are associated with ataxia, confusion, mood disturbances and
drowsiness, with still higher doses inducing amnesia, unconsciousness, respiratory
distress and death, with an LD50 of approximately .4 (for review see Doweiko, 2010).

1.2 Absorption
Ethanol is both water and lipid soluble, facilitating its rapid distribution to all
blood-rich tissues in the body. Due to its high water solubility, concentrations in brain
quickly surpass those in blood, (Kranzler & Ciraulo, 2005). The small intestine provides
the main route of ETOH absorption, however 10-25% of absorption occurs via stomach
lining (Kaplan, Sadock & Grebb, 1994). Ethanol is detectable in blood within one minute
following consumption (Rose, 1988), with its rate of absorption primarily dependent on
the presence of food, which limit alcohol’s ability to diffuse through the stomach lining
and intestinal walls (Sher et al., 2005; for review see Doweiko, 2010).
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1.3 Metabolism & Excretion
The primary metabolism of ETOH occurs in liver via several isoenzymes of alcohol
dehydrogenase (ADH). There are five classes of ADH (1-5), but the hepatic form (in
humans) is primarily Class 1, and is found in stomach and liver. ADH catalyzes the
oxidation of ETOH to acetaldehyde by converting NAD+ to NADH. A secondary
mechanism of ETOH metabolism is the microsomal ethanol oxidizing system (for review
see Lieber, 1999). This system involves metabolism by cytochrome P450, particularly
CYP2E1 (Koop, 2006; Lieber, 2004), also producing acetaldehyde. Acetaldehyde is
unstable, forming free radical structures (discussed in greater depth below) and prolonged
acetaldehyde exposure in liver and kidneys is a major health concern in chronic
alcoholics. Acetaldehyde is converted to acetic acid by acetaldehyde dehydrogenase.
Acetic acid may be excreted in urine, or further reduced to Acetyl-CoA by Acetyl-CoA
Synthetase. Acetyl-CoA can then enter the citric acid cycle, where it is converted to CO2
and H2O (for review see Holford et al., 1987). 90-95% of ETOH elimination in humans is
accounted for by oxidation, with excretion via skin, lungs and kidneys accounting for the
remainder (Holford, 1987).

Copyright © Ben Lewis 2011
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Chapter 2. Pharmacology
In the 1960s, the study of ETOH interactions with ion channels was initiated with
the discovery of its suppressant effect on sodium and potassium currents in squid axons
(Armstrong & Binstock, 1964; Moore, Ulbricht & Takata, 1964). Since that time, it is
difficult to name a receptor/transmitter system whose interaction with ETOH has not
been examined. While a complete review of these interactions is beyond the scope of the
current work, ETOH effects on a number of neurotransmitter systems, with attention to
neuropharmacology thought to relate to its neurotoxic and/or reinforcing effects, will be
discussed.

2.1 ETOH & Dopamine
Although a number of transmitter systems and brain structures contribute to
ETOH’s reinforcing action, alterations in mesolimbic dopamine (DA) is a common
downstream effect. This system is comprised of DAergic projections extending from the
ventral tegmental area (VTA) of the midbrain to the nucleus accumbens (NAcc).
Systemic ETOH injections increase extracellular DA in rodent NAcc (e.g., Blomqvist,
Engel & Nissbrandt, 1993; Diana, Pistis & Carboni, 1993; Di Chiara & Imperato, 1985),
as does voluntary ETOH consumption (Howard et al., 2008), with DA and BAC levels
highly correlated. Additionally, DA increases in human ventral striatum following ETOH
administration, which correlate with subjective euphoria, have been reported (Boileau, et
al., 2003). That mesolimbic DA is involved in ETOH reinforcement is supported by
reductions in ETOH self-administration following DA antagonism in NAcc (Rassnick,
Pulvirenti & Koob, 1992). Activation of mesolimbic circuitry is induced by a number of
ETOH effects, including interaction with glutamate (GLU), nicotinic acetylcholine
(nACh), opiate, serotonin (5-HT) receptors, and gamma-aminobutyric acid (GABA)
receptors (for review see Vengeliene, 2009).

However, while mesolimbic DA activation is necessary for the reinforcing
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properties of many drugs of abuse, ablation of mesolimbic and nigrostriatal systems does
not abolish ETOH consumption in rodents (Kiianmaa et al., 1979; Shoemaker et al.,
2002). Similarly, selective ablation of NAcc fails to disrupt consumption in both
heterogenous (Fahlke et al., 1994; Myers & Quarfordt, 1991) and alcohol preferring
(Ikemoto et al., 1997; Koistinen et al, 2001) rats. These findings do not suggest that
ethanol’s activation of DAergic systems is unimportant, but rather highlight the varied
contribution of numerous systems to consummatory behavior (for review see Gonzales,
Job & Doyon, 2004), in a manner which seems somewhat unique relative to other
substances of abuse.

2.2 ETOH & 5-HT
ETOH potentiates 5-HT receptor function (Lovinger & Zhou, 1994) and increases
5-HT at numerous nuclei throughout brain (McBride et al., 1993; LeMarquand et al.,
1994; for review see Kirby et al., 2011). 5-HT is known to interact with DAergic
systems, modulating mesolimbic DA output. While this interaction is not well
understood, microdialysis studies suggest that 5-HT exposure in the NAcc and striatum
stimulate DA release (Kelland & Chiodo, 1996). Direct synaptic contact between 5-HT
terminals and DA cells in the midbrain supports such an interaction, and provide an
additional mechanism through which ETOH is suggested to exert a reinforcing effect.
However, while it is clear that altering 5-HT function can modulate ETOH selfadministration, contrasting findings in the literature somewhat obscure the mechanistic
contributions to this interaction; increasing 5-HT bioavailability appears to reduce ETOH
intake (Fadda et al., 1991; Hodge et al., 1993), although 5-HTr antagonism of several
receptor subtypes, including 5-HT3 and 5-HT2, also reduces intake (Roberts et al., 1998).

2.3 ETOH & Opiate Systems
The opioid receptor system is composed of metabotropic receptors of at least three
types (μ, δ, κ). Endogenous opioid peptides are known to play a role in the rewarding
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effects of several drugs of abuse, primarily (though not exclusively) through their
modulation of mesolimbic DAergic activity, although such action appears generally
limited to peptides activating the μ and δ receptors. It is now clear that significant
interaction with the opioid system occurs following ETOH exposure (for review see
Hertz, 1997), however the details of much of this interaction remain equivocal. ETOH
appears to increase the density of both μ and δ receptors in animal models (Charness et
al., 1993; for review see Tabakoff et al., 1996). Low to moderate concentrations of
ETOH increase the release of the endogenous μ receptor agonist, beta endorphin, in the
VTA (Jarjour, Bai & Gianoulakis, 2009). Such findings provide another mechanism
through which ETOH exerts reinforcing effects, as activation of VTA-associated μ
receptors enhances DA efflux in NAcc. Additionally, powerful evidence for the
significance of ETOH’s interaction with this system has been elucidated via opioidspecific pharmacological manipulation (reviewed below).

2.4 ETOH & Acetylcholine
ETOH alters the function of neuronal nicotinic acetylcholine receptors (nAChRs).
ETOH enhances the response to nicotine in vivo (Breese et al., 1993) and appears to
interact directly with nAChRs (Aistrup et al., 1999); it is suggested to act as a co-agonist
to ACh at some receptor subtypes, and may function allosterically, increasing agonist
affinity for the receptor (Forman, Righi & Miller, 1989). For example, ETOH increases
responsiveness to nicotine in α2b2, α3b2, and α4b2 receptor subtypes (de Fiebre, Papke
& Meyer, 1995), and potentiates inward currents at α3b4 nAChR subtypes. ACh agonism
in VTA stimulates DA release in NAcc (Li et al., 2008) providing a possible mechanism
of ACh-dependent ETOH reinforcement. However, inhibitory effects have also been
noted (e.g., Covernton & Connolly, 1997), highlighting the complexity of ETOH-nAChR
interactions. Of particular interest, ETOH has been shown to inhibit α7 nAChR subtypes
(e.g., de Fiebre & de Fiebre 2005; Narahashi et al., 1999), with further examinations
suggesting that this α7 subtype is particularly important in modulating several behavioral
and physiological responses to ETOH (Bowers et al., 2005). Additional evidence for
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cholinergic involvement is provided by nAChR antagonists, which attenuate
consummatory responses in a variety of models and species (e.g., Ericson et al., 1998;
Blomqvist et al. 1996).

2.5 ETOH & GABA
GABA is the major inhibitory neurotransmitter in mammalian CNS. ETOH
allosterically modulates the ionotropic GABA-A receptor complex and potentiates
chloride flux through the membrane, resulting in hyperpolarization produced by GABA.
Many behavioral effects of ETOH mimic those of GABA-A receptor agonists, suggesting
the direct involvement of GABA-A receptors in its action. GABA-A receptors are colocalized on DA neurons and GABAergic interneurons in VTA (Xi & Stein, 1998),
facilitating a close interaction between these systems, with mesolimbic DA release
regulated by GABA interneurons (Maldonado et al., 1997). Inhibition of these
interneurons, thought to occur following ETOH exposure, increases NAcc DA release
(Kalivas et al., 1990). GABA appears involved in ETOH’s behavioral effects (e.g.,
ataxia, anesthesia), as GABA-mimetics enhance ETOH-associated behaviors, whereas
functional antagonists decrease them (for review see Deitrich et al., 1989). Interestingly,
such GABA antagonists also appear to reduce consummatory behaviors (Lister &
Linnoila, 1991; Mihic & Harris, 1996; for review see Grobin et al., 1998). While these
findings provide only surface detail concerning the interactions of ETOH in the GABA
system, ample evidence suggests GABA receptor subunit composition and concentration
of ETOH in the system can alter such interactions in a complex manner (for review see
Lobo & Harris, 2008).

2.6 ETOH & Glutamate
Glutamate is the major excitatory transmitter in the mammalian brain. To date,
three groups of G-protein coupled metabotropic GLU receptors (mGluRs) have been
identified; Group I (mGluR1 & mGluR5) activates phospholipase C, producing
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diacylglycerol and inositol triphosphate as secondary messengers, while Groups II
(mGluR2 & mGluR3) and III (mGluR4, mGluR6, mGluR7 & mGluR8) are negatively
coupled to adenylyl cyclase. The mGluRs are responsible for slow glutamate-mediated
neurotransmission and modulation of transmitter release. They couple with G-proteins
and are located throughout the limbic and cortical brain regions implicated in alcoholism,
and in particular, group I mGluRs (mGluR1 and mGluR5) appear important in regulating
the effects of drugs of abuse (Kenny & Markou, 2004).

While mGluRs are almost undoubtedly involved in ETOH action, the ionotropic
GLUrs have received far more attention; three basic receptors families have been
identified, including the N-methyl-D-aspartate receptor (NMDAr), the α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAr) and the kainic acid
receptor (KAr). All three are tetrameric complexes, and are inhibited by ETOH at
physiologically relevant concentrations (Lovinger et al., 1989; Weiner, Dunwiddie &
Valenzuela, 1999; Simson et al., 1991). Fast synaptic transmission within this system is
mediated by AMPAr & KAr, while NMDArs appear to mediate slower synaptic kinetics,
involving Ca2+ and Ka+ flux (for review see Hoffman, 2003).

AMPA receptors are composed of subunits GLUr1-4, which all contain a GLU
binding site. AMPAr are generally permeable to Ca2+, Na+ and K+, although many
contain the Ca2+-impermeable GLUr2 subunit. ETOH inhibition of AMPArs is well noted
(Dildy-Mayfield & Harris, 1992; Lovinger, 1993a; Wirkner et al., 2000) and occurs at a
wide range of concentrations (10-100mM). AMPAr undergo strong desensitization
following agonist exposure (Trussell et al., 1988; Tang et al., 1989), although comparably
weaker and more rapid desensitization following AMPA or GLU exposure (Tang et al.,
1989; Trussell & Fischbach, 1989; Hestrin, 1992; Barbour et al., 1994). Emerging
evidence suggests that ETOH inhibits AMPArs by stabilizing this desensitized state
(Moykkynen et al., 2009). Such inhibition is thought to be noncompetitive, distinct from
channel blockade (Peoples et al., 1997; Wirkner et al., 2000), although interestingly,
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AMPAr do not appear to undergo adaptation following chronic ETOH (for review see
Davis & Wu, 2001).

KA receptors are composed of subunits GLUr5-7 and KA1-2, and can form
homomeric (GLUr only) or heterometric (GLUr5 and KA1-2) stoichiometries (for review
see Dingledine et al., 1999). While initial reports indicated preferential sensitivity of
NMDAr to ETOH, compared to AMPA/KAr (Hoffman et al., 1989; Lovinger et al.,
1989), such sensitivity appears to rely heavily on receptor localization. For instance, KAr
in hippocampal CA3 neurons appear strongly affected by ETOH exposure (Weiner,
Dunwiddie & Valenzuela, 1999). Postsynaptic KArs appear to share a primary cellular
function with AMPArs, both enabling the voltage-dependent functioning of the NMDAr.

2.6.1 NMDAr
The NMDArs are critically involved in the synaptic plasticity associated with
neuronal development, learning & memory (Collingridge & Singer, 1990; Collingridge &
Lester, 1989). It is generally agreed (see Hawkins et al., 1999; Premkumar & Auerback;
1997 for evidence to the contrary) that they are constructed as tetrameric ligand-gated
cation channels, composed of two NR1 and two NR2 subunits (McBain & Mayer, 1994;
Schorge and Colquhoun 2003). Although recent findings have also identified NR3
subunits, these appear to render receptors insensitive to GLU or NMDA and may
assemble with NR1 subunits to form excitatory glycine receptors (Chatterton et al.,
2002), however will not be discussed here. The receptor contains six major binding
domains. The GLU binding site, which also binds NMDA, is located on NR2 subunits;
the Mg2+ binding site is located within the channel, which it blocks under resting
conditions; the MK-801 binding site, which binds other phencyclidine-like compounds is
also found in the channel; the glycine (GLY) binding site is located on NR1 subunits;
polyamine binding sites are located densely on, but not confined to, NR2B subunits
(discussed in the following section); the ifenprodil binding site, which also appears to
bind several structurally related compounds (e.g. eliprodil), is also found on NR2B.
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NMDArs are unique compared to other ionotropic receptors in that ion flux through
the channel relies on three events. Firstly, GLY must bind NR1, co-activating the
receptor. Secondly, GLU (or NMDA) must bind NR2. Finally, GLU must bind AMPArs
or KArs, inducing partial depolarization of the membrane. This partial depolarization
releases Mg2+ from the pore, allowing Ca2+ and Na+ flux through the channel. The
requirement of both GLU binding and partial depolarization of the resting potential allow
the NMDAr to act as a molecular “coincidence detector”, facilitating its roles in longterm potentiation and synaptic plasticity.

Crystallization studies have demonstrated that NR1/NR2 dimers form within the
receptor complex, providing allosteric modulation of gating activity. NR1 subunits are
ubiquitous in brain, and expressed as at least eight splice variants (Nakanishi et al., 1992).
Four NR2 transcripts have been identified (NR2A-D), and are implicated in the
pharmacologic specificity of the receptor, such that various subunit combinations can
differ widely in their pharmacology (Wafford et al., 1993; Monaghan et al., 1998; CullCandy et al., 2001). NR2 subunits appear to determine the synaptic localization and
function of the receptor, as NR2 C-terminal deletion disrupts receptor localization,
activity, and plasticity (Chung et al., 2004). While receptor stoichiometries are clearly
localization-dependent in brain, the degree to which ternary versus binary compositions
are found is a matter of some debate. It has been suggested that NR1/NR2A/NR2B
composition is the most abundant, with binary species present at much lower levels,
however the opposite has also been suggested (Chazot & Stephenson, 1997; Blahos &
Wenthold, 1996). Of particular interest to the current project is the NR2B subunit, for a
variety of reasons; NR2B appear highly plastic, are concentrated in areas known to be
particularly sensitive to ETOH and contain a major binding domain for polyamines.

2.6.2 Polyamines
Polyamines are simple cation compounds, derived from the amino acid arginine.
Arginine can be converted into ornithine, which is then further converted to putrescine
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via ornithine decarboxylase (ODC) the rate limiting step in the synthesis of polyamines.
Alternatively, arginine can be converted to agmatine and then further converted to
putrescine, however this pathway appears to account for only a small portion of
polyamine production. Putrescine is the precursor for two other major polyamines,
spermine and spermidine, converted via spermidine synthase and spermine synthase,
respectively (see Figure 1). These polyamines are ubiquitous in brain, and are involved in
cell proliferation, differentiation, growth and apoptosis (Slotkin & Bartolome, 1986;
Slotkin et al., 2000).
Figure 1. Simplified Polyamine Biosynthesis

Polyamines bind to NMDArs at several sites (Williams et al., 1995; Kashiwagi et
al., 1996; Zheng et al., 1999; Sharma and Reynolds, 1999), and spermine and spermidine
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potentiate GLU-mediated responses by binding to the receptor and allosterically
increasing GLU binding affinity (Williams, 1997a). Putrescine appears to act differently,
exhibiting some antagonistic effects (Romano et al., 1992). Due to the diminished
implication of putrescine in NMDAr activity, and its significantly lower concentration in
brain (4-70 nM/g vs. 50-1400 nM/g for spermine/spermidine; Seiler and SchmidtGlenewinkel, 1975; Shimizu et al., 1964), for the purposes of this dissertation
‘polyamines’ will refer primarily to spermine and spermidine. Polyamines exert this
effect even in the presence of saturating concentrations of GLY (‘GLY-independent
stimulation’; Benveniste & Mayer, 1993; Lerma, 1992; Rock & Macdonald, 1992),
however a GLY dependent mechanism has also been noted, with polyamines increasing
the affinity of GLY binding (GLY-dependent stimulation; Benveniste & Mayer, 1993;
McGurk, Bennett & Zukin, 1990). Furthermore, voltage-dependent inhibition, possibly
involving polyamine interaction within the channel has also been noted (for reviews see
Dodd, 2000; Williams, 1997b). Subunit composition appears to strongly influence the
aforementioned effects. For instance, GLY-dependent stimulation appears to occur
regardless of composition (in NR2A/2A, 2B/2B and 2A/2B stoichiometries), while GLYindependent stimulation is favored by a composition including NR2B subunits (for
review see Williams, 1997). While polyamines are known to affect NR2A-containing
receptors, it is the presence of NR2B which appears to confer polyamine sensitivity
(Williams et al., 1994; Gallagher et al., 1997; Sharma and Reynolds, 1999).

2.6.3 NMDArs and ETOH
Behavioral and molecular examinations strongly implicate the NMDAr in the acute
actions of ETOH. Early in vitro studies have demonstrated ETOH’s inhibition of
NMDAr-mediated transmission (Lovinger, et al., 1989; Hoffman et al., 1989). Since then,
such observations have been confirmed and elaborated upon by examining slices in
cortex (Wright, Peoples & Weight, 1996; Wirkner et al., 2000), amygdala (Calton,
Wilson & Moore, 1998), NAcc (Maldve et al., 2002; Nie, Madamba & Siggins, 1994),
dorsal striatum (Yin et al., 2007; Wang et al., 2007; Popp et al., 1998) and hippocampus
(Wright, Peoples & Weight, 1996; Lovinger, White & Weight, 1990; Morrisett, 1991;
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Kolb, Trettel & Levine, 2005). While the literature has focused on post-synaptic
mechanisms of inhibition, more recent evidence suggests ETOH interactions with the
receptor may also involve a presynaptic component (Hendricson et al., 2004; Zhu et al.,
2007). It remains unclear exactly how and where ETOH binds the receptor; it does not
appear to block the channel (Reynolds & Rush, 1990), to compete with GLU binding
(Abdollah & Brien, 1995), polyamine binding (Matsumoto et al, 1993), Mg2+ or Zn2+
binding (Morrisett et al., 1991; Chu et al., 1995). However, evidence for ETOH
occupation of hydrophobic pockets (Peoples & Weight, 1992; Ren et al., 2003; Ronald et
al., 2001) has been observed, which suggests ETOH functions allosterically to alter
channel-gating properties and is consistent with observations of its wide-ranging
pharmacology.

NMDArs appear involved in the discriminatory stimuli involved in ETOH
exposure. NMDAr antagonists substitute for ETOH in two-choice discrimination
(Bienkowski et al., 1996; Kotlinska and Liljequist, 1997; Grant, 1999; Holter et al.,
2000). While such discrimination studies clearly implicate the NMDAr as a primary
target of ETOH, the recognition that GABA-A or 5-HT agonists can also substitute for
ETOH in drug discrimination highlight both the complexity of its CNS action, and its
lack of selectivity for any single transmitter system (Hodge & Cox, 1998; Grant, 1999;
Hodge et al., 2001). It is known that the training dose of ETOH used in discrimination
studies alters the degree to which NMDAr antagonists can act as substitutes, with higher
concentrations involving a stronger NMDAr component (Colombo & Grant, 1992; Green
& Grant, 1998). This is particularly interesting, suggesting that at higher doses
(associated with AUDs), the NMDAr may become a more important target for ETOH,
and thus perhaps a more important target for pharmacological intervention in treating
alcoholism.

ETOH inhibition of NMDAr function appears to depend, at least in part, on subunit
composition. Receptors containing NR2A and/or NR2B subunits appear to display much
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greater sensitivity to alcohol than those including NR2C or NR2D (Kuner et al., 1993;
Mirshahi & Woodward, 1995; Masood et al., 1994; for reviews see Allgaier, 2002;
Sucher et al., 1996). However, whether NR2A or NR2B is the critical subunit for ETOH
interactions remains a matter of some debate. Early studies suggested ETOH targeted
NR2B-containing NMDArs (Lovinger, 1995; Fink & Gothert, 1996), however such
claims were at least partially refuted with demonstrations in the cerebellum, where NR2C
is abundantly expressed (Popp et al., 1999). Furthermore, examinations in hippocampus
have produced divergent results, suggesting both NR2A (Suvarna et al., 2005) and
NR2B-specific (Izumi et al., 2005) action. Such examinations are further complicated by
the lack of NR2A-specific NMDAr antagonists, the suggestion that NR1 splice-variant
expression affects sensitivity (Jin & Woodward, 2006) and noted differences in
sensitivity depending on expression system (Smothers et al., 2001). A recent study
utilized NR2A knockout mice to demonstrate equivalent ETOH inhibition of both
knockout and wild types, suggesting the presence of NR2A is not a requirement for
NMDAr inhibition (Kash et al., 2008), however, this demonstration was conducted in the
ventral bed nucleus of the stria terminalis, and while supported by other examinations
(Roberto et al., 2004; Izumi et al., 2005), these results may be unique to the regions
studied. While NR2A-specific interactions are still being explored, the current literature
suggests a substantial interaction with NR2B-containing NMDArs, which is further
described and explored in the current project.

Exposure to ETOH is known to change NMDAr function and expression,
particularly following chronic and/or binge-like exposure, and during withdrawal (WD)
from ETOH. NMDAr upregulation appears to occur following chronic treatment (for
reviews see Tabakoff & Hoffman, 1996; Kumari & Ticku, 2000). Ligand binding and
autoradiography has demonstrated increases in receptor number following chronic
exposure (Grant et al., 1990; Gulya et al., 1991; Snell et al., 1993), however examinations
of subunit alterations reveal some inconsistencies. It seems that following chronic
exposure, NR2B may be upregulated in cortex (Follesa & Ticku, 1995; Kalluri et al.,
1998) and hippocampus (Hardy et al., 1999; Follesa & Ticku, 1995; Kalluri et al., 1998),
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however some examinations failed to detect this upregulation (Chandler et al., 1997).
Importantly, while much of this literature utilizes rodents, ETOH-associated increases in
NR2B have been noted in humans (Biermann et al., 2007; Biermann et al., 2009).

ETOH-related NR2A increases in hippocampus are found consistently (Kalluri et
al., 1998; Follesa & Ticku, 1995; Snell et al., 1996). However, cortical increases were
detected by some groups (Follesa & Ticku, 1995; Chandler, 1999), but not others (Snell
et al., 1996; Hu et al., 1996; Follesa & Ticku, 1996a; 1996b; Chandler et al., 1997). NR1
examinations have been similarly inconsistent, with upregulation detected in
hippocampus by some (Snell et al., 1996; Trevisan et al, 1994; Kalluri et al., 1998), but
not others (Follesa & Ticku, 1995), and in cortex by some (e.g., Chandler et al., 1999;
Kalluri et al., 1998) but not others (e.g., Snell et al., 1996; Hu et al., 1996). While the
variables contributing to such inconsistent results have not yet been fully elucidated, the
basic finding that ETOH increases subunit expression, resulting in enhanced NMDAr
agonist sensitivity, is well supported. Furthermore, polyamines appear to play a complex
role in mediating effects of ETOH on the NMDAr (Davidson and Wilce, 1998; for review
see Littleton et al., 2001), and are increased following chronic exposure. The
implications of both subunit and polyamine increases are thought to be far-reaching for
dependence, relapse, and ETOH-associated neurotoxicity, areas which are primary foci
of the current work, and which are discussed at length in their respective sections, below.

Copyright © Ben Lewis 2011
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Chapter 3. ETOH-Associated Brain Damage
AUDs are associated with cognitive deficits and neurodegeneration, although even
moderate drinking has been associated with reduced cognitive function (Evert & OscarBerman, 1995). A subset of alcoholics display deficits in intellectual functioning, with
the most prevalent impairments including visuo-spatial ability and higher cognitive
function (Oscar-Berman et al., 1997). Imaging studies have revealed reductions in brain
size and density (Pfefferbaum, et al., 1988; Pfefferbaum et al., 1992), most noticeable in
cortex and cerebellum, regions in which brain activity also appears altered in heavy
drinkers (Eberling & Jagust, 1995). Fortunately, many such deficits in structure and
function appear at least partially reversible during abstinence (e.g., Sullivan et al., 2000;
Sullivan, Rosenbloom & Pfefferbaum, 2000). Of particular relevance to the current work,
cognitive impairments appear most severe during and immediately following acute WD
(Allen, Goldstein & Seaton, 1997).

3.1 Mechanisms of Damage
The proposed mechanisms underlying deficits originating from either adulthood or
fetal exposure are numerous: oxidative stress, non-oxidative metabolites (e.g., fatty acid
ethyl esters), malnutrition, HPA-axis dysfunction, intracellular microtubule disruption
and excitotoxic cellular damage have all been implicated (Butterworth, 1995). While
multiple mechanisms undoubtedly contribute to ETOH-induced damage, the current work
focuses on GLU and disrupted GLUr function, which appear to play primary roles. While
ubiquitous, and crucially important to homeostatic function, GLU can also be toxic; it is
implicated in the pathogenesis of a wide variety of disorders, including ischemia
(Hammerman & Kaplan, 1998), amyotrophic lateral sclerosis (for review see Bogaert et
al., 2010), AIDS and/or HIV-associated dementia (Prendergast et al., 2002; Self et al.,
2004), neuropathic pain (for review see Brown & Krupp, 2006), Parkinson’s disease
(Bonuccelli and Del Dotto, 2006), epilepsy (Tzschentke, 2002) and Huntington’s disease
(Fan et al., 2007). GLU over-activation of NMDArs, leading to excessive Ca2+ entry, can
induce several intracellular cascades which lead to both necrotic and apoptotic cell death.
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This pathological excitation of the receptor is termed ‘excitotoxicity’ and appears to
occur, at least in part, due to increases in NMDAr expression and sensitivity following
chronic ETOH exposure (e.g., Hoffman et al., 1995; for review see Lovinger., 1993). A
major underlying hypothesis of the current project is that ETOH-associated cell death
and neurodegeneration involves this hyper-excitable state, resulting in excitotoxic injury
during withdrawal.

While the toxicity of GLU has been recognized for some time (Lucas & Newhouse,
1957), this was followed by the identification of Ca2+ increases as a major contributor
(Choi et al., 1985; Choi et al., 1987). Increases in intracellular Ca2+ may be achieved via
multiple mechanisms, however, NMDAr-mediated Ca2+ entry has been critically
implicated; higher concentrations of Ca2+ from alternate sources have been shown to be
less toxic than lower concentrations whose source was NMDAr-mediated (Tymianski et
al., 1993; Sattler, Charlton & Hafner, 1998). One proposed mechanism for the NMDArspecificity of excitotoxicity involves its intracellular coupling to neuronal nitric oxide
synthase (nNOS; Sattler, Xiong & Lu, 1999); increased NO is a hallmark of excitotoxic
events and major contributor to damage. NOS inhibitors are known to prevent cell death
in vitro (Dawson et al., 1991), and resistance to NMDAr-mediated excitotoxicity is
conferred by nNOS knockout (Dawson, Kizushi & Huang, 1996). The structural link
between NMDAr and nNOS appears to involve a postsynaptic density protein associated
with the C-terminus of the NR2B subunit and N-terminus of nNOS, creating a
“microenvironment” wherein Ca2+ entering the cell via NR2B-containing NMDArs
preferentially activate nNOS via calmodulin (Sattler, Xiong & Lu, 1999). NO appears to
directly interact with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to initiate
apoptotic cascades (Hara et al., 2005), as well as the free radical superoxide, forming
toxic peroxynitrite. Free radicals are highly reactive molecules formed during
mitochondrial reactions with oxygen during energy production. Free radicals and
peroxides are collectively referred to as reactive oxygen species (ROS) and when
overproduced under pathological conditions, damage several intracellular structures
including proteins, lipid membranes (Sun et al., 1997) and nucleic acids (Navasumrit et
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al., 2000). “Oxidative stress” generally refers to both increases in ROS-associated
intracellular damage (Reinke et al., 1987; Henderson et al., 1995; Davis et al., 1990), and
reductions in the cell’s ability to compensate (Bailey et al., 2001). Excitotoxicity and
oxidative stress are frequently dissociated in the literature as differential pathways of cell
death, however the role of NO in excitotoxicity illustrates the interconnected nature of
these pathways. ROS production following excitotoxicity is well-established (Dugan,
Sensi & Canzoniero, 1995; Reynolds & Hastings, 1995) and appears dose-dependent
with increased NMDAr activation (Lafon-Cazal et al., 1993). In sum, the literature
suggests a model wherein excessive intracellular Ca2+ accumulation via NMDArs
pathologically increases NO production and results in mitochondrial failure. ROS
produced by such failure interact with NO to form peroxynitrite, directly damaging DNA
and leading to the release of apoptosis-inducing factors from mitochondria, resulting in
cell death (for review see Lau & Tymianski, 2010).

3.2 Excitotoxicity & Polyamines
Polyamines may play a critical role in ETOH-associated excitotoxicity; increased
polyamine expression has been reported in hippocampus, striatum, cortex, and
cerebellum during periods of ETOH WD (Davidson & Wilce, 1998; Gibson et al., 2003).
Increases in ODC expression (indexing increases in polyamine concentration) are noted
in these areas following chronic ETOH exposure (Koenig et al., 1990; Shibley et al.,
1995; Davidson & Wilce, 1998). Additionally, polyamine activity seems to correlate
positively with behaviors indexing the severity of WD-associated damage, including
WD-induced tremor and seizure in dependent animals (Davidson & Wilce, 1998).
Additionally, reductions in ODC activity correlate with reductions in severity of WD
symptoms (Davidson & Wilce, 1998). In vitro examinations of WD-induced excitotoxic
damage suggest that exogenous application of polyamines exacerbates damage (Butler et
al., 2010; Mayer et al., 2002a), while polyamine antagonism (Gibson et al., 2003)
attenuates damage. Furthermore, inhibition of polyamine synthesis via difluoromethyl
ornithine, an ODC inhibitor, inhibits WD-induced seizure, improves WD-associated
outcomes in vivo (Davidson & Wilce, 1998), and attenuates cell death in vitro (Gibson et
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al., 2003). Taken together, this evidence suggests that the withdrawal state can be
characterized by increases in polyamine-sensitive (NR2B-containing) NMDArs as well
as increases in polyamine synthesis and accumulation. This suggests that polyamine
modulation during WD may provide a useful substrate for pharmacotherapeutic
intervention. Further evidence for this hypothesis is garnered from examinations of
compounds that inhibit polyamine-sensitive NMDArs (reviewed below in section 5).

Copyright © Ben Lewis
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Chapter 4. ETOH Dependence
The aforementioned evidence implicates the GLU system in ETOH-associated
neurotoxicity, however the selection of this system as a pharmacological target in the
current project is also due to its contribution to ETOH dependence and withdrawal. While
numerous neurotransmitter systems are involved, GLUergic intervention seems uniquely
capable of reducing relapse risk through multiple mechanisms, including positive and
negative reinforcement, as well as alterations in cue conditioning and salience.

4.1 Acute & Protracted Withdrawal
Cessation of chronic ETOH consumption is associated with the alcohol withdrawal
syndrome, characterized by autonomic hyperactivity, increased tremor, nausea/vomiting,
anxiety, hallucination, psychomotor agitation and seizure (APA, 2000). Recent estimates
suggest up to 2 million Americans experience symptoms of alcohol withdrawal per year
(Bayard et al., 2004). Although acute withdrawal is potentially life-threatening,
detoxification has become a routine medical procedure which rarely results in mortality
(for review see Romach & Sellers, 1991). Current detoxification practices involve
GABAergic manipulation via benzodiazepines, and are extremely effective at controlling
withdrawal symptoms and morbidity, however there is no evidence for reductions in
neurotoxicity or relapse risk following treatment. The current project focuses on
developing compounds with the capability of reducing both toxicity and relapse.
Withdrawal can be characterized by increased glutamatergic activity and increased
stress/anxiety. While the most severe withdrawal symptoms generally dissipate within 12 weeks, symptomology and underlying altered brain function can persist for months, and
possibly much longer. It is hypothesized that such altered glutamatergic function and
negative affect during both acute and protracted withdrawal contribute to increased
relapse risk.
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4.1.1 Glutamatergic Hyperactivity
Extracellular concentrations of GLU appear increased following withdrawal, and
are highly correlated with withdrawal symptomology (Gonzales et al., 1996; Rossetti &
Carboni, 1995). The hyperexcitability during withdrawal appears mediated by NMDArs,
whose upregulation following chronic exposure is well-established; a similar syndrome
of hyperexcitability is noted following withdrawal from chronic NMDAr antagonism
(Ripley & Little, 1995). Furthermore, GLU inhibition during withdrawal reduces
symptom severity (Grant, 1990; Liljequist, 1991; Morrisett et al., 1990; Rossetti &
Carboni, 1995) while agonism worsens it (Danysz et al., 1992; Davidson et al., 1995;
Morrisett et al., 1990; Sanna et al., 1993). As noted above, elevations in polyamines
appear to contribute to this hyperactivity, and polyamine inhibition is also capable of
reducing WD symptoms (Davidson & Wilce, 1998).

GLU hyperactivity also appears to contribute to ETOH dependence and relapse
(Tsai & Coyle, 1998; Pulvirenti & Diana, 2001; Siggins et al., 2003; Heinz et al., 2003;
Krystal et al, 2003). Although the exact mechanisms are still being investigated, GLUmediated increases in cue salience and incentive motivation for ETOH during withdrawal
are implicated. Additionally, GLU hyperactivity may exacerbate negative affect during
withdrawal, indirectly increasing cue salience and ETOH reinforcement further. Though
discussed in greater detail below, a simple schematic of these relationships is presented in
Figure 2.
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Figure 2. Contributions of ETOH Withdrawal to Reinforcement and Cue Salience

4.1.2 Stress, Anxiety & Negative Affect
Withdrawal from chronic ETOH increases anxiety (Rassnick et al., 1993; Valdez
et al., 2002). Stress & anxiety during withdrawal appear closely related to resumption of
drinking in humans (Hershon, 1977). Stress responses are controlled by the
hypothalamic-pituitary-adrenal (HPA) axis; basic functioning of this system involves
CNS stimulation of corticotropin-releasing hormone from hypothalamus, inducing
pituitary secretion of adrenocorticotropin, resulting in adrenal glucocorticoid (GC;
cortisol, in humans) production. Alcohol intoxication and withdrawal are known to
increase GCs (Adinoff et al., 1991; Keedwell et al., 2001; Mendelson et al., 1971), with a
number of implications. Hippocampal GCrs, via negative feedback, are responsible for
regulating HPA-axis activity and recovery. Chronically elevated GC levels and chronic
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ETOH binge/WD cycles are known to induce hippocampal damage, disrupting negative
feedback control and dysregulating the HPA system (for review see Adinoff et al., 1998).

Both GLU hyperactivity and disrupted HPA-axis activity are thought to contribute
to relapse behaviors by altering ETOH reinforcement and ETOH-associated cue salience,
as indicated in Figure 2. However, these systems also appear to interact with one another
dynamically during withdrawal. GC exposure upregulates polyamine-sensitive NR2B
subunit expression (Lu et al., 2003), as well as increasing the production of polyamines.
(Weiland, Orchinik & Tanapat, 1997). Finally, GC elevations upregulate excitatory
amino acid activity, increasing Ca2+ flux via NMDAr (for review see, Reagan &
McEwen, 1997; Armanini et al., 1990). However, inhibition of GLUrs is anxiolytic
(Dunn et al., 1989; Faiman et al., 1994), protects from GC-associated hippocampal
neurotoxicity (Mulholland et al., 2005), and reduces WD-associated behaviors indexing
stress (Cagetti et al., 2004).

Taken together, these interactions suggest that GLU inhibition during withdrawal
may serve to balance GLU activity both directly, as well as indirectly, by preventing
increased GC activity via neuroprotection to critical (hippocampal) stress-regulation
circuitry. Thus, reductions in GLU activity are likely to reduce negative affect and HPAaxis dysregulation, both critical contributors to relapse.

4.2 Relapse & ETOH Reinforcement
Following cessation of chronic drinking, the majority of dependent individuals
will experience a relapse, despite efforts to maintain sobriety (Hayashida et al., 1989;
Prochaska, DiClemente, & Norcross 1992). Preventing relapse is a (if not the) major
therapeutic challenge in treating ETOH dependence. Contemporary theories of relapse
hold that following chronic consumption and cessation, drug-associated alterations in
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neurochemistry contribute to a state in which the reinforcing value of the drug is
increased during sobriety.

Positive reinforcement is indicated when a stimulus (alcohol) increases the
probability of a particular response (consumption or ETOH-seeking behavior). Negative
reinforcement is indicated when the probability of the response is increased when it
allows for escape or alleviation from an aversive stimulus (e.g., anxiety). It is now
generally agreed that the pathogenesis of alcoholism can be described as a transition from
motivation to consume ETOH based on its positive reinforcement, to compulsive use
associated with its alleviation of the negative affective state created during WD. This
conceptualization of addiction, wherein use becomes driven by homeostatic maintanance
has been described as ‘allostasis’ originated with Himmelsbach (1943) following his
work in opiate dependence, and was not described as ‘allostasis’ until much later
(Sterling and Eyer, 1988). Allostasis describes the dynamic adaptation of multiple
systems to achieve (or restore) homeostatic function, making it a particularly apt
description of the varied physiological adaptations to drugs of abuse noted in dependence
& addiction. Allostasis has become a primary, driving conceptual model in the field (e.g.,
Koob & Le Moal, 2001; Koob & Volkow, 2010).

While progression from positive to negative reinforcement as a basic concept has
been popularized, it potentially ignores a subset of individuals with high stress/anxiety
prior to initiation of use, whose primary initial motivation to consume may involve
ETOH’s anxiolytic properties. Regardless of initial motivation, following the cessation of
chronic consumption, ETOH-exacerbated negative affect is thought to persist for months
or longer, is referred to as “protracted withdrawal” and is characterized by stress, anxiety,
depression and hyperalgesia (Koob, 2003). Thus, heightened negative reinforcement for
consumption of ETOH appears to remain persistent despite the absence of acute
withdrawal symptoms. However, sensitization to the positive reinforcing value of ETOH
may also contribute to its enhanced reinforcing value during withdrawal.
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Conceptualizations of conditioning and relapse based on positive vs. negative
reinforcement can be referred to as ‘incentive salience’ vs. ‘opponent-process’ models,
respectively. Incentive salience models suggest that drug cues will produce conditioned
drug-like responses (euphoria), which enhance the incentive motivation to consume the
drug. Opponent-process models suggest that with prolonged drug use, physiological
‘drug-opposite’ responses to conditioned cues develop to maintain homeostasis. In a
drug-free state, exposure to such cues produces a dysphoric state in which the negative
reinforcing value of the drug is increased. Importantly, both of these views hold that
relapse involves a state wherein the increased reinforcing value of drugs is “triggered” by
environmental cues.

It is clear that ETOH has both positive (euphoric, stimulating) and negative
(anxiolytic) reinforcing effects. DA efflux in NAcc has received the most attention as a
biological requirement for positive reinforcement, however as noted above, mesolimbic
dopamine is modulated by input from a number of transmitter systems (including GLU).
Pharmacological interventions which reduce DA efflux or blunt its effects are noted for
their ability to disrupt ethanol consumption in humans and animals (discussed in greater
depth below). Glutamate tone, NAcc DA levels, ETOH consumption and ETOH’s
positive reinforcing value all appear closely related; NAcc DA levels increase in
anticipation of ETOH consumption, suggesting an important role for cue-associated
increases in positive reinforcement during relapse (Katner, Kerr & Weiss, 1996;
Melendez et al., 2002). Furthermore, manipulation of NAcc GLU via microinjection of
GLUr inhibitors (including NMDAr antagonists) reduces drinking (Rassnick, 1992;
Besheer et al., 2010), emphasizing the GLUergic component of ETOH’s reinforcing
effects.

In one particularly interesting study, Spanagel and colleagues (2005) genetically
altered astrocytic GLU transporter expression to create mutants with persistently high
synaptic GLU activity (as is known to occur in ETOH withdrawal). These mutants
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demonstrated increased ETOH intake and increased operant responding for ETOH.
Further demonstrating GLUergic control of the behavior, Spanagel’s group
pharmacologically inhibited the GLU hyperactivity and observed normalized
consumption. However, while this work appears to implicate GLUergic mechanisms in
positive reinforcement (since the animals received no aversive stimuli or previous ETOH
exposure) an alternative interpretation suggests that such persistently high synaptic GLU
activity may produce a negative affective state, potentially driving consumption. This
interpretation is consistent with observations that the negative reinforcing properties of
ETOH are also mediated via GLUrs.

That ETOH reinforcement can also be driven by negative components is
emphasized by the finding that ablation of the mesolimbic DA system fails to extinguish
ETOH consumption (Rassnick et al., 1993). A major underlying hypothesis of the current
project is that inhibition of GLUergic activity during acute and protracted withdrawal can
mitigate negative affect, thereby reducing ETOH’s negative reinforcing value.
Supporting evidence includes that GLU inhibition can reverse or attenuate dysregulation
in HPA-axis function (described above) and that numerous compounds with GLUergic
action which are shown to reduce consumption and relapse behavior (clinically and
preclinically) possess anxiolytic action. Finally, amygdalar nuclei which regulate
negative affect, particularly anxiety and fear responses, are implicated as key modulators
of ETOH reinforcement and appear sensitive to GLU imbalance. The basolateral
amygdala is rich in GLU receptors (Farb et al., 1995; for review see Davis et al, 1994;) as
is one of its major efferents, the central nucleus (CeA; Nose et al., 1991; Davis et al.,
1994). GLU levels in these areas are persistently higher in animals chronically exposed to
ETOH (Roberto et al., 2004), contributing to the anxiogenic properties of WD. Similarly,
reductions in GLUergic transmission in these areas, whether due to ETOH or NMDArspecific antagonism, produce anxiolytic effects (Miserendino et al., 1990; Kim et al.,
1993). Of particular importance to the current project, amygdalar neuroadaptations to
chronic ETOH appear mediated by NR2B-containing NMDArs; CeA NR2B upregulation
is persistent (> 4 weeks; Obara et al., 2009) following chronic exposure and the
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heightened sensitivity of CeA NMDArs to ETOH observed following such exposure is
attenuated via NR2B-specific antagonism (Roberto et al., 2004).

Taken together, the aforementioned evidence suggests that (i) ETOH consumption
is under the control of both positive and negative components of reinforcement; (ii) that
both positive and negative components are mediated at least in part by GLU; (iii) and that
GLU inhibition, specifically NMDAr inhibition, appears capable of reducing both types
of reinforcement.

4.2.1 Conditioned Cues
Changes in the reinforcing value of ETOH during withdrawal increase relapse
risk, serving to prime the system for relapse, however cues or “triggers” which reinstate
the conditioned behavior of alcohol seeking are also critically involved. In traditional
conditioning models, environmental cues (including ETOH itself, referred to as ‘priming’
cues) become associated with alcohol use, after which they function as classically
conditioned stimuli, evoking conditioned physiological responses. These appear to induce
alcohol-related effects that can include feelings of euphoria (drug-similar responses)
and/or feelings of withdrawal (drug-opposite responses referred to as “conditioned
pseudo-withdrawal” (Solomon, 1980; O’Brien et al., 1998), both of which may result in
‘craving’ or the desire to experience alcohol’s effects. As mentioned previously,
divergent models of relapse/reinforcement conceptualize craving as being driven by
either euphoric or dysphoric feelings, however contributions are likely to vary on an
individual basis and it is suggested that even within individuals craving and relapse may
be precipitated by a variety of environments and/or internal states (Connors et al., 1996).
Regardless of reinforcement mechanism, extinction of these conditioned cues appears to
improve relapse measures (Glautier & Drummond, 1994).
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Protracted relapse constitutes a period of heightened stress and anxiety, during
which acute stressors are known to trigger conditioned relapse (Annis, 1998; Sinha et al.,
2000; for review see Sinha, 2001). Interestingly, acute stress also appears to have a
permissive function, enhancing the salience of other conditioned ETOH cues (Field &
Powell, 1997). This may be a bi-directional relationship, since (as opponent-process
theory would predict), exposure to alcohol cues via guided imagery in abstinent
alcoholics increases negative affect (Cooney et al. 1991, Sinha et al., 2000). However,
stress-induced relapse appears to operate via dissociable neural mechanisms from cueinduced relapse; Liu & Weiss (2002) demonstrated that opioid antagonism could
attenuate cue-induced, but not stress-induced reinstatement of drinking, while a CRF
antagonist suppressed stress-induced, but not cue-induced consumption. When animals
were simultaneously exposed to both conditioned cues (a situation with greater face
validity to human behavior), both the CRF and opioid antagonist were only capable of
partial mediation. Their experiment highlights the complexity of relapse/reinstatement
behavior, and suggests that an ideal pharmacological intervention would be capable of
attenuating both stress and cue-induced reinstatement.

As suggested in Figure 2, in addition to impacting reinforcement, the GLUergic
system is critically involved in the conditioning and expression of ETOH-associated cues.
ETOH cue-induced reinstatement of self-administration has been demonstrated and
attenuated in dependent animals via GLU inhibition (e.g., Backstrom & Hyytia, 2004).
Additionally, GLU inhibition reduces responding for ETOH-associated cues in
conditioned place preference studies (McGeehan & Olive, 2003; Brown, Lee & Sorg,
2008; Gremel & Cunningham, 2009). More recent examinations have suggested specific
GLUr subpopulations, particularly NMDArs containing polyamine-sensitive subunits,
may be critical for drug-associated conditioning. In general, polyamines are known to
enhance learning and memory processes (Rubin et al., 2000; 2001; Mikolajczak et al.,
2002), including cue-associated conditioning (Rubin et al., 2004). However, inhibiting
NMDArs via polyamine modulation reduces drug-associated responding while leaving
responding for natural reinforcers intact (Ma et al., 2006). Although not yet examined
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directly, these findings suggest that known increases in polyamine expression and
sensitivity during ETOH withdrawal may enhance conditioned responding to alcoholassociated cues.

Taken together, evidence presented in the preceding sections suggests that chronic
ETOH exposure is associated with neurotoxicity and pathological alterations in both
GLU and HPA-axis function. These changes are associated with increases in the
reinforcing value of ETOH, and increased sensitivity to ETOH-conditioned cues, both of
which increase relapse risk. The complexity and range of the involved mechanisms
suggests numerous substrates for pharmacological intervention (discussed below),
however based on evidence discussed above, inhibition of polyamine-sensitive NMDArs
may provide a unique opportunity to simultaneously reduce excitotoxicity, GLU
hyperactivity and negative affect during WD, the downstream effects of which include
reductions in reinforcing value (positive and negative) of ETOH and sensitivity to ETOHconditioned cues. Additional evidence for this hypothesis is garnered from examinations
of a number of pharmacological interventions, presented below.

Copyright © Ben Lewis 2011
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Chapter 5. Pharmacotherapy
While the current work is focused on mediation of ETOH-associated alterations in
physiology and behavior via NMDAr-targeted pharmacotherapy, several FDA-approved
pharmacological interventions already exist, as do a number of potentially useful
strategies which do not target the NMDAr. Disulfiram and naltrexone are discussed here,
while the third FDA-approved compound (acamprosate) will be discussed with other
GLUergic compounds, below.

5.1 Disulfiram
Disulfiram (Antabuse) has been FDA-approved since 1951. Disulfiram inhibits the
enzyme acetaldehyde dehydrogenase (ADH), stimulating a number of negative symptoms
normally associated with WD (“hangover”) from ETOH (e.g., nausea, vomiting). It is
unique in that it acts indirectly, providing a punishing stimulus when ETOH is consumed.
Early studies reported high efficacy, while later results have been more mixed.
Regardless, the most recent data indicate that with supervised use, which greatly
improves patient compliance, disulfiram has clinical utility (for review see Fuller &
Gordis, 2004).

5.2 Naltrexone
Naltrexone (ReVia, Depade) was FDA-approved in 1995; its extended release
formula (Vivitrol) was approved in 2006. Both naltrexone and its active metabolite, 6-βnaltrexol, competitively antagonize opioid receptors, particularly μ receptors, leading to
reductions in NAcc DA levels (Benjamin & Grant, 1993; Gonzales & Weiss, 1998;
Middaugh et al., 2003). Such reductions are associated with reduced ETOH consumption,
as has been shown in several clinical studies (Latt et al., 2002; Krystal et al., 2001), as
well as demonstrated by the multi-center COMBINE study, which suggested efficacy
when administered apart from adjunct psychotherapeutic intervention (Anton et al.,
2006). Such recognized efficacy has been demonstrated by a number of meta-analyses
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(e.g., Kranzler & Van Kirk, 2001; Streeton & Whelan, 2001; for review see Anton, 2008;
Bouza et al., 2004). Naltrexone is recognized to reduce craving associated with
environmental cues, reducing conditioned anticipation of ETOH (Monti et al., 1999;
Middaugh & Bandy, 2000), however such reductions are likely to result from blunting of
incentive motivation associated with ETOH, rather than weakened cue conditioning.

5.3 Current Promising Strategies
While not yet FDA-approved, a number of additional pharmacotherapeutic agents
are currently being investigated for abstinence maintenance and relapse prevention (for
review see Johnson et al, 2008). Several do not employ GLUergic manipulation; for
instance, specific serotonin reuptake inhibitors (SSRIs) have been employed in a number
of preclinical models, with mixed results. It appears that SSRI treatment is capable of
reducing ETOH consumption and operant responding for ETOH (Haraguchi, Samson &
Tolliver, 1990; Murphy et al., 1988). However, evidence suggests that such attenuations
may be non-specific, resulting in suppressions of food and fluid intake (Simpson et al.,
1981; for review see Gill & Amit, 1989). Furthermore, it is suggested that while SSRIs
are capable of initial reductions in consummatory behavior, rebound to baseline levels are
noted (Gulley et al., 1995). Clinical investigations appear to produce short-term decreases
in consumption, but many have limited longevity: there is evidence that initial decreases
do not persist after the first month of treatment (Gorelick & Paredes 1992; for review see
Kenna, 2010). However, it is recognized that SSRIs may have unique utility among
ETOH-dependent populations with comorbid depressive symptoms (Pettinati et al.,
2010).

While restoring homeostatic GLU tone during and after WD is a focus of the
current work, agonism of GABAr to restore GLU/GABA balance has also been explored.
For instance, the GABA-B agonist, baclofen, decreases consumption (Colombo et al.,
2000; Colombo et al., 2002), operant responding for ETOH (Colombo et al., 2003a) and
reduces relapse-behavior (Colombo et al., 2003b), preclinically. In humans, baclofen
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shows efficacy in reducing cravings and improving abstinence (Addolorato et al., 2000;
for review see Leggio et al., 2010), effects which may be related to reductions in WDassociated anxiety and negative affect. While promising, clinical examinations of
baclofen are limited, and it’s noted sedative properties may interact negatively with acute
ETOH intoxication.

Given the aforementioned involvement of the HPA axis in WD, protracted
withdrawal, and the negative reinforcing effects of ETOH, it is not surprising that direct
manipulation of this system has been investigated as a pharmacotherapeutic strategy.
Antagonists of corticotropin-releasing factor (CRF) have received significant attention; it
is known that ETOH WD increases CRF levels (Merlo Pich et al., 1995; Olive et al.,
2002), and that CRF antagonists attenuate stress and anxiety responses (Britton et al.,
1986). Thus, CRF antagonists appear capable of attenuating ETOH WD-induced stress
responses (Baldwin et al., 1991). Interestingly, CRF antagonists, while anxiolytic in
nature, appear capable of reducing ETOH consumption in models that other anxiolytics
(e.g., diazepam) do not, perhaps suggesting the specific modulation of HPA-axis function
is necessary, as opposed to general reduction in anxiety/negative affect (Lodge &
Lawrence, 2003).

Additional investigations include cannabinoid receptor antagonists, DAr
antagonists (e.g., aripiprazole), DAr agonists (e.g., bromocriptine), 5-HT antagonists (e.g.
ritanserin), 5-HT agonists (e.g., buspirone), nAChR antagonists (e.g., varenicline), and
others. While all have demonstrated some clinical potential, many have significant side
effects or show efficacy only in limited clinical populations. Furthermore, and perhaps
most importantly for our strategic approach, neither of the aforementioned FDAapproved compounds, nor these experimental approaches, are noted for significant
neuroprotection.
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5.4 Acamprosate
The current project focuses on GLUergic manipulation, a key characteristic of
which may be the ability to alter relapse trajectories while offering neuroprotection
during acute and protracted withdrawal (an ability which may synergize with anti-relapse
mechanisms). However, this is not a novel area of investigation. A number of GLUergic
manipulations have been explored, both clinically and preclinically, and the third FDAapproved medication, acamprosate, is thought exert its effects primarily via GLUergic
action.

Acamprosate (Campral) is structurally related to a number of amino acids thought
be to critically important to ETOH’s CNS actions, including GLU, GABA and GLY
(Spanagel & Zieglgansberger, 1997). These similarities contribute to its varied
pharmacology (for reviews see Littleton, 1995; Littleton et al., 2001; De Witte et al.,
2005; Mann et al., 2008); it is recognized as an anti-oxidant (Dahchour et al., 2005),
GABA-A agonist (Pierrefiche et al., 2004), NMDAr antagonist (Zeise et al., 1993),
polyamine modulator (Al Qatari et al., 1998; Naassila et al., 1998; Popp & Lovinger,
2000), and Group I mGLUr antagonist (Harris et al., 2002). Despite FDA approval, the
mechanism of action contributing to its anti-relapse efficacy is equivocal. However, it
appears capable of normalizing elevated extracellular GLU following repeated binge-WD
cycles (Dahchour & De Witte, 2003; Ulrichsen et al., 1998), and it is generally agreed
that this action contributes to reductions in the negative reinforcement of ETOH during
WD and protracted withdrawal. In animal models, acamprosate inhibits WD-associated
behaviors (Spanagel & Ziegelgansberger, 1997), reduces relapse behavior (Spanagel et
al., 1996), suppresses conditioned pseudo-withdrawal behavior (Cole, Littleton & Little,
1999) and attenuates cue-induced ETOH-seeking behaviors (Bachteler et al., 2005).
Clinically, acamprosate appears effective at reducing a number of behavioral endpoints
associated with relapse-risk and abstinence maintenance (Mason et al., 2006; Feeney et
al., 2006).
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Additionally, acamprosate appears to confer neuroprotection, reducing toxicity and
Ca2+ entry in neocortical cultures (Al Qatari et al., 2001). In hippocampal cultures, which
are used in the current project, acamprosate attenuates WD-associated Ca2+ entry and
neurotoxicity (Mayer et al., 2002a;b), however acamprosate appears to have a unique
neuroprotective profile, thought to include mGLUr manipulation, as it is noted to inhibit
ETOH WD-associated toxicity but not NMDA-associated toxicity (Harris et al., 2003).

The varied GABAergic and GLUergic interactions of acamprosate are similar in
nature to topiramate (Topamax). In animal models, topiramate reduces stress-induced
relapse behaviors (Farook et al., 2009) and ETOH cue-conditioned behaviors during WD
(Farook et al., 2007). Clinically, the drug appears efficacious (Johnson et al., 2003;2007),
and may share acamprosate’s neuroprotective potential (Rustembegovic et al., 2002).

5.5 Memantine
A number of GLUergic approaches have utilized NMDAr-specific antagonists.
Classic channel-blockers are noted for their lack of clinical potential, however, lowaffinity, non-competitive antagonists appear to induce rapidly dissociating channel
blockade and may have anti-relapse efficacy. One such compound in particular,
memantine, has received attention. Due to its rapid dissociating kinetics, memantine is
thought to interfere less with homeostatic NMDAr transmission, compared to classic
channel blockade (Chen & Lipton, 1997; Bleich et al., 2003; Johnson & Kotermanski,
2006; Lipton, 2006; for review see Kohr, 2007). It has shown anti-relapse potential
(Krupitsky et al., 2007a) in humans, and appears to reduce WD symptoms (Krupitsky et
al., 2007b). Memantine is also recognized for its neuroprotective potential in models of
excitotoxicity (Lipton, 2007) including ETOH WD (Stepanyan et al., 2008). One
criticism of an NMDAr-blockade strategy involves the potential disruption of learning &
memory; MK-801 disrupts responding for natural rewards (Lee & Everitt, 2008; Bevins
& Bardo, 1999), as does memantine (Popik et al., 2003). However, as noted previously,
NR2B-specific antagonism may provide a solution, disrupting drug-associated cues while
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leaving cues for natural reinforcers unperturbed (Ma et al., 2006).

5.6 Ifenprodil & Eliprodil
Due to the recognized contribution of the NR2B in ETOH-associated WD, cueconditioning and neurotoxicity, investigation of compounds capable of targeting NR2Bcontaining subpopulations has been substantial. One such compound is ifenprodil, which
is characterized as a non-competitive allosteric inhibitor of the spermine and Mg2+
binding sites, whose action exhibits use-dependence, such that bound GLU increases the
receptor’s affinity for ifenprodil (Kew et al., 1998). A secondary mechanism of
inhibition, shared by ifenprodil and its analogue CP-101,606 (described below), involves
proton inhibition. NMDArs are inhibited by protons with an IC50 value that corresponds
to pH 7.3 (e.g., Giffard et al., 1990; Tang et al., 1990; Traynelis & cull-Dandy, 1990).
While this mechanism is largely understudied, a major function of such proton sensitivty
appears related to its neuroprotective capacity during acidification of the extracellular
space, noted during seizures and ischemia, during which pH can fall by up to 1 pH unit
(e.g., Chesler & Kaila, 1992). Under conditions of excessive extracellular GLU, such
decreases in pH appear to limit NMDAr-mediated excitotoxicity (Kaku et al., 1993). In
the presence of ifenprodil (and CP-101,606), NMDAr sensitivity to protons is increased,
providing an additional mechanism of antagonistic activity (Mott et al., 1998). It is likely
that proton inhibition is a mechanism shared by phenylethanolamines in general (i.e.,
eliprodil and others), however this has yet to be demonstrated empirically.

Ifenprodil has shown promise as a neuroprotectant during excitotoxic events,
reducing edema and infarct volume in ischemia models (for review see Wang & Shuaib,
2005), improving outcomes in reserpine & MPTP models of Parkinson’s (Nash et al.,
1999; Nash et al., 2000) and models of neuropathic pain (for review see Chizh &
Headley, 2005). Such neuroprotection extends to in vitro ETOH WD-associated
neurotoxicity (Mayer et al., 2002a), and it appears protective in vivo as well, based on
attenuation of WD-associated seizure behaviors (Pawlak et al., 2005; unpublished data).
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Eliprodil is an ifenprodil analogue, maintaining high specificity for NMDARs containing
the NR2B subunit (Avenet et al., 1997), and has shown similar efficacy as a
neuroprotectant in several models of excitotoxic injury (Toulmond et al., 1993; Bath et
al., 1996; Reyes et al., 1998). Eliprodil’s neuroprotective action has been investigated in
developmental models of insult; administration during acute WD rescues adulthood
behavioral deficits in rodent FAS models (Thomas et al., 2004).

Ifenprodil & eliprodil appear to have more modest inhibitory effects (compared
with non-subunit selective compounds) synaptically, where diverse populations of
NMDArs are found, including NR1/NR2A and NR1/NR2B diheteromers as well as
NR1/NR2A/NR2B triheteromers (Tovar & Westbrook, 1999). However, extrasynaptic
populations of NMDArs appear more homogenous, composed primarily of NR1/NR2B
diheteromers (Tovar & Westbrook, 1999), and thus are strongly inhibited by ifenprodil.
The synaptic localization of NMDArs appears to determine their opposing effects on
gene regulation and neuronal survival; synaptic receptors induce anti-apoptotic effects,
while Ca2+ entry via extra-synaptic NMDArs elicits loss of CREB function, reduced
BDNF expression and ultimately mitochondrial dysfunction and cell death (Hardingham
et al., 2002). Thus, NR2B-specific antagonism may exert its neuroprotection via
extrasynaptic NMDAr inhibition, while largely preserving synaptic function.

Additionally, ifenprodil appears to reduce ETOH consumption in a relapse model
examining binge-like consumption following periods of forced abstinence, known as the
alcohol-deprivation effect (ADE), a procedure also utilized in the current project (Sinclair
& Senter, 1967). Furthermore, ifenprodil has been shown to block ETOH’s stimulatory
effects (Broadbent, Kampmueller & Koonse, 2003), suppress ETOH WD effects in
dependent rodents (Narita et al., 2000, Malinowska et al., 1999) and attenuate ETOH’s
amnestic effects (Napiórkowska-Pawlak et al., 2000). Interestingly, NR2B-containing
NMDArs appear to play an important role in behaviors related to other drugs of abuse.
For instance, ifenprodil is known to block both CPP induction and expression for
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morphine (Suzuki et al., 1999; Ma et al., 2006; Ma et al., 2007). Similarly, treatment with
an antibody against NR2B subunits abolishes morphine-induced place preference,
whereas antibodies against NR2A do not (Narita et al., 2000). These results suggest that
examination of NR2B-specific compounds as anti-relapse agents for alcohol may inform
research examining other drugs of abuse.

While examinations of eliprodil and ifenprodil have returned promising results,
and further implicated NR2B involvement in ETOH action, their clinical development
has been slowed due to secondary effects including calcium channel blockade as well as
alpha-adrenergic, 5HT1A, 5HT2, 5HT3 and sigma receptor inhibition (Chenard et al.,
1991; McCool & Lovinger, 1995; Biton et al., 1994). Although additional receptor
system activation does not necessarily preclude clinical advancement, the aforementioned
pattern of activation suggests complex cardiovascular and affective complications.

5.7 CP-101,606
Recent medication development efforts altered the composition of ifenprodil at
several sites, producing a similar compound (see Figure 3), CP-101,606 (1S,2S)-1-(4hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol (Pfizer). Radioligand
binding studies have determined that CP-101,606 (CP) represents a distinct class of
NR2B specific antagonists, which bind NR2B with high affinity only if the receptor is an
NR2B/NR2B diheteromer (Chazot et al., 2002). This high degree of specificity is thought
to limit its side effect profile in humans, suggesting its potential for clinical use in
alcoholism. Additionally, this NR2B/NR2B specificity provides a unique pharmacological
tool with which to investigate NR2B involvement in ETOH-associated relapse and
neurotoxicity, and was thus selected as one of the compounds examined in the current
project.
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Figure 3. Molecular Structure of Ifenprodil and its Analogue, CP-101,606

Thus far, CP has received limited attention in alcohol research, but has been used
in several other fields. CP has shown efficacy as an antinociceptive agent (Boyce et al.,
1999), an anticonvulsant (Brackett et al., 2000) and has demonstrated anti-parkinsonian
action (Nash et al., 2004; Steece-Collier et al., 2000). CP attenuates the effects of
traumatic brain injury and focal ischemia in animal models (Okiyama et al., 1998;
Okiyama et al., 1997; Tsuchida et al., 1997; Di et al., 1997; Kundrotiene et al., 2004) and
protects hippocampal neurons from glutamate toxicity in vitro (Menniti et al., 1997), and
of particular relevance to the current project, CP was used in a cortical cell culture model
of ETOH WD, and demonstrated the ability to reduce excitotoxic effects in vitro (Nagy et
al., 2004).

Furthermore, our own work has demonstrated CP’s neuroprotective potential.
Following chronic, neonatal ETOH exposure, a single administration of CP during
withdrawal was able to attenuate a number of behavioral deficits reliably produced by
this FAS model, including balance deficits, hyperactivity and learning & memory
dysfunction (Lewis et al., submitted).

In experimental mammals, CP seems to have few side effects; it neither impedes
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motor performance (Boyce et al., 1999) or learning and memory as measured in Morris
water maze (Guscott et al., 2003). In contrast to other NMDAr antagonists, it may
enhance performance in cognitive tasks (Higgins et al., 2005). Importantly, CP has been
used in several clinical studies, where it appeared well-tolerated (Johnson et al., 2003;
Merchant et al., 1999); two in particular report positive reduction in the behavioral
consequences of stroke and traumatic brain injury (Yurkewicz et al., 2005; Bullock et al.,
1999). Due to the mechanistic contributions of polyamine-sensitive NMDArs in
neurotoxicity and relapse, and due to the noted safety and potential of CP-101,606, it was
selected for use in the current project.

5.8 Agmatine & Our Current Development Strategy: Novel Polyamine Modulators
Agmatine (decarboxylated L-arginine) was recognized approximately a century
ago (Kossel, 1910) but identified in mammalian brain only within the last few decades
(Li et al., 1994). The accumulated evidence suggests agmatine meets the criteria of a
central modulator, and is currently considered a putative neurotransmitter (for review see
Halaris & Plietz, 2007). Agmatine is synthesized in neurons (Reis & Regunathan, 2000;
Iyo et al., 2006); is released presynaptically in a Ca+ dependent manner (Goracke-Postle
et al., 2006); is disrupted by exogenous drugs (I1r antagonists; Wu, Su & Liu, 2006); is
distributed in specific neuronal populations (i.e., hippocampal; Reis, Yang & Milner et
al., 1998); has specific reuptake processes (Reis & Regunathan, 1998; Sastre, Regunathan
& Reis, 1997), is enzymatically degraded (i.e., agmatinase; Sastre et al., 1996; Iyer et al.,
2002); and acts on receptors (e.g., Olmos et al., 1999; Piletz et al., 1995; Askalany et al.,
2005), effecting specific neuronal processes (e.g., nNOS inhibition; Demady et al., 2001).

The action of agmatine most relevant to the design of the current project involves
its ability to act as an endogenous modulator of polyamine activity, functioning as a low
potency NMDAr inhibitor, however it appears unique for several reasons, including its
ability to inhibit or inactivate nNOS by up to 50%, at physiologically relevant
concentrations (Auguet et al., 1995; Galea et al., 1996; Demady et al., 2001). NMDArs
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and nNOS are both recognized for their contribution to glutamatergic neuroplasticity,
suggesting agmatine may provide unique modulation of such neuroplasticity, unattainable
via either NMDAr or nNOS-selective manipulation. The observation that agmatine is
increased in hippocampus (~85%) following training of learning-dependent tasks (Morris
maze) supports this suggestion, however the functional significance of increased
agmatine is unknown. Furthermore, its unique NMDAr/nNOS profile suggests its
prophylactic potential for excitotoxic damage (given the closely related involvement of
both NMDAr and nNOS). Initially, reports of agmatine’s physiological concentration in
CNS were low (pM-nM), however it is now recognized that acute stress or trauma may
induce rapid agmatine synthesis, such that >10 μM concentrations have been noted
following insult (Aricioglu, Regunathan & Piletz, 2003).

Of further significance, particularly in terms of its consideration as a therapeutic
agent or lead compound, agmatine appears only a very weak channel inhibitor, with an
IC50 of approximately 1 mM, significantly lower than other polyamine modulators
ifenprodil or arcaine (IC50s of 500 nM and 5 μM, respectively). However, agmatine
exhibits a Ki of ~15 μM for MK-801 binding in the presence of spermidine (100 μM;
Ring, 2006), suggesting its ability to inhibit the NMDAr is polyamine-specific, at
relevant concentrations.

Agmatine’s noted neuroprotective potential (e.g., Gibson et al., 2003; Gilad et al.,
1996; Lewis et al., 2007), anxiolytic effects (Lavinsky, Arteni, & Netto, 2003),
attenuation of drug-associated conditioning (Wei et al., 2005), and reduction of ETOH
WD symptoms (Uzbay et al., 2000) have generated interest in its clinical development for
a range of diseases including schizophrenia (Uzbay et al., 2009), neuropathic pain (Onal
et al., 2003) and substance abuse disorders. Recently, agmatine’s clinical efficacy as an
antinociceptive agent was demonstrated in subjects suffering herniated lumbar discassociated radiculopathy (Keynan et al., 2010). While Kenyan & colleagues observed
only mild-to-moderate side effects, concerns about uraemia (Piletz et al., 2003) and toxic
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interactions with elevated potassium levels (Abe, Abe & Saito, 2003) are noted. One
alternative to direct agmatine administration involves agmatinase inhibition (e.g.,
piperazine carboxamidine), a solution being explored currently (Huang et al., 2003). The
current project has selected another strategy, using agmatine as a lead structure for the
development of novel, higher potency, agmatine analogues.

To this end, we established a medications development screening project at the
University of Kentucky, wherein novel molecules were synthesized in the Pharmaceutical
Sciences Division of the College of Pharmacy and examined in molecular screens for
polyamine inhibition. Compounds testing positive were then examined in simple cellular
screens, followed by more complex tissue screens, simple behavioral screens and finally
complex behavioral screens, all contingent on success in the previous tier of screening.

The primary molecular screen involved detection of [3H]MK-801 binding in
membrane preparations, both in the presence and absence of spermidine. MK-801 is an
open-channel ligand, whose Bmax is enhanced by approximately 75-100% when
spermidine is added to the membrane preparation (Gibson et al., 2002). In this screen,
compounds acting via competitive inhibition or steric hindrance display a monophasic
binding curve, reducing [3H]MK-801 binding regardless of the presence or absence of
spermidine. Compounds which display biphasic curves, such that at low concentrations
[3H]MK-801 binding is only reduced in the presence of spermidine, are thought to
display selectivity for polyamine inhibition. Over 1500 compounds have been screened in
this manner, including a group of aryliminoguanidines. One member of this group, JR220 ([4-Chlorobenzylidenamino]-guanidine Hydrochloride; see Figure 4), was highly
potent, with an IC50 of 3.6 μM.
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Figure 4. Molecular Structure of Agmatine and its Analogue, JR-220

The neuroblastoma cell line SH-SY5Y expresses functional GLUergic cells and
receptors, and is used in the current project to screen novel compounds for their ability to
inhibit NMDA-induced 45Ca2+ entry. JR-220 (JR) was shown to inhibit calcium entry in a
concentration-dependent manner with greater potency (10-100 μM) than agmatine (100500 μM). Neuroprotection of SH-SY5Y cells from NMDA insult (500 μM) at saturating
concentrations of glycine and spermidine (10 μM and 100 μM, respectively), was
assessed using the colorimetric assay, MTT. JR-220 significantly and concentrationdependently (10-100 μM) reduced toxicity. This cell line was further used to screen for
protection from ETOH withdrawal-associated damage (with identical concentrations of
glycine and spermidine) after a 4-day exposure (180 mM). JR-220 (10-50 μM)
demonstrated the highest neuroprotective capability in this screen. Importantly, when
these SH-SY5Y experiments were conducted without adding exogenous spermidine, JR220 failed to show efficacy at aforementioned doses, consistent with the hypothesis that
JR-220’s mechanism of NMDAr inhibition is polyamine-dependent.
Given its success in the aforementioned molecular and cellular experiments, JR-220 was
selected to continue advancement through our screening procedure and is the focus of
the current work.

Copyright © Ben Lewis 2011
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Chapter 6. Hypotheses & Project Summary
The hypothetical framework for the current project conceptualizes the behavioral and
cellular alterations associated with chronic ethanol consumption as being driven in large
part by persistent alterations in glutamatergic tone and function, and being reversible via
NMDAr antagonism.
HYPOTHESIS 1: Compounds which selectively inhibit polyamine stimulation of the
NMDAr will perform positively in predictive screens for
attenuation of a wide range of ETOH-associated effects and
behaviors. Specifically:
Hypothesis 1a) JR-220 will reduce both in vitro and in vivo (convulsion) indications of
neurotoxicity
Hypothesis 1b) JR-220 will reduce cue-conditioned withdrawal behavior
Hypothesis 1c) JR-220 will reduce drinking behaviors associated with both positive and
negative reinforcement, including stress, relapse, and binge screens.
HYPOTHESIS 2: Compounds which selectively inhibit polyamine stimulation in a
subset of NMDArs containing NR2B/2B diheteromers will be
sufficient for positive performance in our predictive screens.
Specifically:
Hypothesis 2a) CP-101,606 will reduce both in vitro and in vivo (convulsion) indications
of neurotoxicity.
Hypothesis 2b) CP-101,606 will reduce drinking behaviors associated with both positive
and negative reinforcement, including stress, relapse, and binge screens.
HYPOTHESIS 3: Selective polyamine inhibitors which perform positively in our
predictive screens will demonstrate efficacy in standardized,
established models of pathological ETOH consumption.
Specifically:
Hypothesis 3a) JR-220 will reduce consumption in the ‘Drinking in the Dark’ model.
Hypothesis 3b) CP-101,606 will reduce consumption in the ‘Drinking in the Dark’
model.
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Experiments presented here were conducted in the context of a drug discovery
project, designed to identify novel compounds with the potential to reduce withdrawal
severity, neurotoxicity and relapse risk. The current work presents a subset of screens
from this project. The included screens have been validated with relevant drugs (i.e.,
acamprosate, topiramate, memantine), with one notable exception (see below). Screens
include a complex organotypic hippocampal culture screen designed to assess
neuroprotective potential (Experiment 1), a simple behavioral screen designed to assess
withdrawal severity (Experiment 2) as well as several more complex behavioral screens
designed to examine cue-conditioning during withdrawal (Experiment 3), relapse-like
drinking behavior (Experiment 4), stress-associated consumption (Experiment 5) and
binge-like drinking behavior (Experiment 6). Though not directly examining drinking
behavior, a final behavioral screen (Experiment 7) was included to assess potential
anxiety-related and/or activity-related effects of the compounds tested. Finally, a model
of binge-like drinking was utilized to further examine screening results (Experiment 8).

The primary compound of interest for the current project is JR-220, a modulator
of polyamine enhancement of NMDAr function. Data generated from the examination
of JR-220 in Experiments 1-6 will directly test Hypothesis 1. CP-101 was examined both
due to its therapeutic potential as well as its unique pharmacological profile, which may
help illuminate the contribution of NR2B-containing NMDArs to the behaviors examined
here. Although only examined in Experiments 1, 2, and 6, data generated from these
experiments will directly test Hypothesis 2. Based on the results of these screens, we
utilized a well-recognized model of binge-like consumption (Experiment 8) to further
explore these compounds. While Experiment 8 will directly test Hypothesis 3, it does not
represent a complete examination, but rather the first in a series of planned explorations,
the entirety of which are beyond the scope of this dissertation.

Copyright © Ben Lewis 2011
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Chapter 7. Methods, Results & Discussion (By Experiment)
Experiments presented here represent screens which were developed based on
several well-established models of ETOH intake behavior, as well as some lesser-known
paradigms (e.g., Experiment 3). We use Sprague-Dawley rats as well as Swiss Webster
and C57BL6J mice. Species/strains were selected based on either established literatures
suggesting the appropriateness of our chosen species/strains (Experiments 1,2,5 and 6) or
the experiences of our group in establishing these paradigms (Experiment 3). The
exception is Experiment 4; Wistar rats are the most common strain used (P rats are also
common) in the model from which this screen was established; Sprague-Dawley rats
were selected for pragmatic reasons (our group maintains an established Sprague-Dawley
breeding program and has extensive experience with this strain). However, using wellestablished methods (discussed below) we have repeatedly demonstrated the paradigm’s
utility with this strain. The information above is described in Table 1.
Table 1. Species/Strain Use by Experiment

Exp.

Screen/Model

Species/Strain

(Strain-specific) References

1

Hippocampal Slice Culture
(OHSC)

Rat: Sprague-Dawley
(In vitro)

(e.g., Stoppini et al., 1991; Gibson et al., 2003;
Prendergast et al., 2000; Stepanyan et al.,
2008; Noraberg and Zimmer, 1998)

2

Handling-Induced
Convulsion (HIC)

Mouse: Swiss Webster

(e.g., Farook et al., 2007; Stepanyan et al.,
2008; Crabbe et al., 1980)

3

Conditioned Withdrawal in
Elevated Plus Maze (EPM)

Mouse: Swiss Webster

(Farook et al., 2007; Wilson et al., 1998*; Cole
et al., 1999*; Cole et al., 2000*)
* used TO Mice, derived from Swiss Websters.

4

Alcohol Deprivation Effect
(ADE)

Rat: Sprague-Dawley

* The use of Sprague-Dawleys is atypical;
Wistars and P rats are used most commonly.

5

Stress-Associated Drinking

Mouse: C57BL/6J

(Farook et al., 2009; Lopez et al., 2011)

6/8

Drinking in the Dark (DID)

Mouse: C57BL/6J

(e.g., Rhodes et al., 2005; Rhodes et al., 2007;
Moore & Boehm, 2009; Gupta et al., 2008)

All species/strains

(e.g., Rubin et al., 2008; Wellmann et al.,
2011)

7

Open Field (OF)

a
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Preclinical models (both in vivo and in vitro) have three basic measures of
validity. Construct validity describes the extent to which the physiological mechanisms or
underlying pathophysiologies are similar between the cellular/animal models and
humans. Face validity describes the extent to which the model mimics the behaviors or
symptoms exhibited in the human disease. Construct and face validities are historically
the models more heavily weighted when considering the usefullness of a particular
model. However, for the purposes of drug discovery, predictive validity, or the ability to
predict a drug’s action and/or efficacy in humans, is considered critical. The challenge for
establishing predictive validity is generally the need for an efficacious pharmacotherapy
in humans to use as a benchmark with which screen results may be compared. While
these data are not shown, Experiments 1-5 were previously validated with several
relevant compounds, including ifenprodil, memantine, and most importantly,
acamprosate, which was considered a ‘best-in-class’ reference drug both for its efficacy
in treating human alcoholics as well as its putative mechanisms of action, which most
closely resemble (compared to other FDA-approved drugs) those of our compounds.
In the development of our screens and screening procedure, predictive validity
was the most strongly considered, since high throughput screening with strong predictive
validity should have the greatest power to identify potential compounds of interest, which
can then be tested more thoroughly in models with face and construct validity (this idea is
well represented in our transition from simple screens to Experiment 8). Designations of
‘screen’ and ‘model’ are particularly challenging in the current work, which utilizes both.
In the context of this project, ‘screen’ is used to describe an experiment whose primary
function involves prediction of, rather than direct evidence for, efficacy. Experiment 2
(described in detail below) illustrates this concept; the elicitation of convulsions during
artificially exacerbated ETOH withdrawal fails to resemble clinically-manifested
behaviors, but predicts modulatory actions at the receptor level which resemble current
NMDAr-directed pharmacotherapies. It is thusly considered a screen, rather than a
model. While Experiments 2 and 8 provide clear examples of screens and models,
respectively, other experiments are less easily dissociated, and although selected for their
predictive validity, offer significant face and construct validities.
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Experiment 1: Organotypic Hippocampal Slice Culture (OHSC)
Although numerous in vitro models have been utilized to examine
neuroprotection from excitotoxic insult, our complex in vitro screen required a paradigm
which could efficiently characterize the effect of pharmacological agents in live brain
tissue. The organotypic hippocampal slice (OHSC) procedure uses a brain area known to
be particularly vulnerable to ETOH, and is conducive to the type of screening procedure
used here. The procedures described here were originally developed by Stoppini and
colleagues (1991), and produce hippocampal slices containing live, intact neurons and
glia, maintaining a high level of complex neuronal connection and surviving in an
apparently healthy state for extended periods of time (Stoppini et al., 1991). This method
has been used extensively by our group (e.g., Gibson et al., 2003; Prendergast et al.,
2000; Stepanyan et al., 2008) and others (e.g., Noraberg and Zimmer, 1998) to
investigate chronic ETOH exposure and WD. Importantly, the OHSC screen has been
validated with a number of highly relevant compounds. Ifenprodil (Gibson et al., 2003),
memantine (Stepanyan et al., 2008) and acamprosate (Mayer et al., 2002a) have all been
shown to reduce excitotoxic insult during/following ETOH withdrawal in this model.
Furthermore, the contribution of polyamines to damage in this paradigm is established, as
evidenced by attenuated damage following DFMO treatment (Gibson et al., 2003) and
exacerbated damage following exogenous polyamine application (Mayer et al., 2002b),
suggesting its particular sensitivity as a screening tool for polyamine modulators.

While described in detail below, the procedure involves extracting hippocampi
from rat pups, plating the slices in hormone/nutrient-rich media and chronically exposing
the slices to ETOH. Upon removal of the ETOH, significant CA1 toxicity occurs. In the
studies presented here, various concentrations of JR-220 and CP-101,606 were examined
for their ability to prevent this withdrawal-associated excitotoxicity. In all conditions
slices were exposed to exogenous NMDA, either a toxic dose (20 μM) or a mild dose (5
μM), which does not induce significant toxicity (unpublished data). This mild dose was
used to model excessive GLU influx from hippocampal afferents during WD. The
competitive NMDAr antagonist MK-801 was also included as a treatment. [5 μM
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NMDA] alone was used as a negative control, while [20 μM NMDA] and [5 μM NMDA
+ MK-801] provided positive controls (indicating maximal toxicity and protection,
respectively). Cell death was indexed by fluorescence of propidium iodide (PI), which
binds DNA, entering via compromised cell membranes (Zimmer et al., 2000). This index
of cell damage has been validated by several other markers (Wilkins et al., 2006).
Specifically, we hypothesized that both CP and JR would reduce ETOH WD-associated
PI fluorescence in CA1, a direct measure of cellular damage.

Subjects
Sprague-Dawley rats used in the current project were born in our breeding
facility at the University of Kentucky (UK) Psychology Department. Parent animals were
obtained from Harlan Labs (Indianapolis, IN). Animals were mated nightly, and the
presence of a seminal plug the following morning indicated copulation had occurred.
Pregnant females were individually housed in plastic cages in a temperature controlled
nursery (70±3° F) on a 12:12 light:dark cycle (on at 0700h, off at 1900h) with food and
water provided ad libitum. On the day following birth (PND1) litters were culled to 10
animals, maintaining a 1:1 sex ratio when possible. All research was conducted in
accordance with the guidelines of the National Institute of Health Guide for the Care and
Use of Laboratory Animals (NIH Publications No. 80-23, 1996) and approved by the
University of Kentucky Institutional Animal Use and Care Committee.

Hippocampal Extraction & ETOH Exposure
PND8 Sprague-Dawley rat pups were used in all OHSC experiments. Pups from
11 litters were sacrificed (3 males/3 females, per litter) via rapid decapitation, brains
aseptically removed, and transferred to ice-cold dissecting media [Minimum Essential
Medium (MEM; Gibco BRL, Gaithersburg, MD), 25 mM HEPES (ATCC, Manassas, VA),
200 mM L-glutamine (Invitrogen, Carlsbad, CA), 50 μM streptomycin/penicillin (ATCC,
Manassas, VA)]. Following removal of the meninges, hippocampi were removed, sliced
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coronally at 200 μm (McIllwain Tissue Chopper; Campden Instruments Ltd., Lafayette,
ID) and plated in triplicate onto 0.4 μm Biopore membranes (Millipore, Marlborough,
MA). Membranes were suspended in 1 ml culture media [dissecting media, 36 mM
glucose, 25% Hanks’ balanced salt solution (HBSS; Gibco BRL, Gaithersburg, MD),
25% heat-inactivated horse serum (HIHS; Sigma, St. Louis, MO)] using six-well plates.

Plates were incubated at 37 °C in a 5% CO₂/21% O₂/74% N₂ medical grade gas
composition for 5 days in vitro (DIV) to allow affixture to the membrane. On the fifth
day in vitro (DIV 5) the plates were treated with new culture medium, with half exposed
to 100mM ETOH. This media change was repeated on DIV 10. Between media changes,
plates were housed in airtight plastic chambers with humidity and ethanol vapor
concentrations maintained by placing 50 ml of 100 mM ETOH into the chambers; control
chambers received 50 ml of water instead of ETOH. The chamber environment was filled
with an identical composition of medical grade gas before being sealed and placed back
into the incubator.

NMDA Challenge & ETOH Withdrawal
On DIV 15, a final media change was conducted, with ETOH-free media
containing PI (2.5 μg/ml, Molecular Probes, Eugene, OR) added to each well. Well
treatments included 5 μM NMDA (5N), 20 μM NMDA (20N; used as a negative control),
5 μM NMDA + MK-801 (20 μM; used as a positive control) and 5 μM NMDA + Drug
(e.g., JR). In order to reduce litter effects and facilitate comparison between groups,
treatments were divided across subjects such that no treatment was repeated within a
single subject in either the ETOH or control condition. Figure 5 illustrates an example of
assigned treatments in a particular culture.
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Figure 5. Treatment Distribution Within a Single Culture

Imaging & Analysis
PI uptake was visualized at 5x objective using a Leica DMBIRM microscope (W.
Nuhsbaum Inc.; McHenry, IL) fitted for fluorescent detection (Mercury-arc lamp), and
imaging software (SPOT Advanced, version 4.0.2, W. Nuhsbaum Inc.; McHenry, IL). PI
fluorescence was analyzed using Image J, v1.29x (National Institutes of Health,
Bethesda, MD). Dentate gyrus (DG), and cornu ammonis regions 1 (CA1) and 3 (CA3)
were all analyzed. For each slice, background fluorescence was subtracted from the
region of interest prior to analysis. Fluorescence was recorded in arbitrary units, then
converted to percent of control, facilitating comparison across multiple cultures and
controlling for variation between litters. Two-way analyses of variance (ANOVAs) were
conducted (Sex x Treatment) on a regional basis. If no effect of sex was detected, sex was
collapsed in further analyses. If the initial ANOVA was significant, planned comparisons
(Fisher’s protected t) were conducted to compare treated slices to their appropriate
controls (ETOH-exposed or ETOH-naïve). Experiments with JR utilized six litters
(N=217), distributed across 20 treatment groups, as depicted in Table 2. Experiments
with CP utilized five litters (N=177), distributed across 16 treatment groups, as depicted
in Table 3.
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Table 2. JR-220 Treatments & Subjects

Table 3. CP-101 Treatments & Subjects
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JR-220 Results
Images of representative slices are presented in Figure 12, following these results.
CA1
In CA1, administration of JR reduced fluorescence in ETOH-treated slices at all
concentrations. No toxicity in ETOH-naïve slices was noted. The initial overall analysis
revealed an effect of TREATMENT, F(18, 193)=27.633, p<.001, in CA1. No effect of
sex was detected. Planned comparisons (Fisher’s protected t) revealed that in ETOHtreated groups, fluorescence was significantly reduced by MK and all concentrations of
JR (p<.001, p<.001, p=.003, p<.001, p=.001, p=.010, p=.002, p=.021, p<.001,
respectively) . Fluorescence was increased following 20 μM NMDA treatment (p<.001),
as expected. A second set of planned comparisons conducted among ETOH-naïve slices
indicated differences only in the positive and negative control conditions; increased
flouresence following 20 μM NMDA treatment (p<.001) and decreases following MK801 treatment (p=.004) were noted. Figure 6 depicts PI uptake in the CA1 region relative
to controls.
Figure 6. JR-220 in CA1
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CA3
In CA3, administration of JR reduced fluorescence at the lowest dose, while
appearing toxic at 100 μM. An overall ANOVA revealed a main effect of TREATMENT,
F(18, 193)= 6.301, p<.001, in CA3. No effect of sex was detected. Planned comparisons
(Fisher’s protected t) revealed that fluorescence differed between the ETOH control
group and four other ETOH-exposed groups. In the case of MK-801 (p=.013) and 50 μM
JR (p=.023) this difference reflected reduced PI uptake, while in the cases of 20 μM
NMDA (p<.001) and 100 μM JR (p=.024), increased uptake was observed. Among
ETOH-naïve slices, 20 μM NMDA increased uptake (p<.001). Figure 7 depicts PI uptake
in the CA3, relative to controls.

Figure 7. JR-220 in CA3
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DG
In DG, 100 μM JR was associated with increased fluorescence, no other effects
were noted. An overall ANOVA revealed a main effect of TREATMENT, F(18, 193)=
4.982, p<.001, in DG. No effect of sex was detected. Planned comparisons (Fisher’s
protected t) revealed only a difference between ETOH-exposed 20 μM NMDA slices and
controls (p=.001). Among ETOH-naïve slices 100 μM JR was associated with increased
fluorescence (p=.018), as was 20 μM NMDA (p<.001). Figure 8 depicts PI uptake in the
DG, relative to controls.

Figure 8. JR-220 in DG
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CP-101,606 Results
CA1
In CA1, administration of CP reduced fluorescence in ETOH-treated slices at low
concentrations, but was associated with toxicity at higher concentrations in both ETOH
and ETOH-naïve groups. The overall ANOVA revealed a main effect of TREATMENT,
F(14, 155)=21.338, p<.001, in the CA1. No effect of sex was detected. Planned
comparisons (Fisher’s protected t) revealed decreased PI uptake in 10 nM CP (p<.001),
25 nM CP (p<.001) and MK-801 (p<.001) treated slices, relative to ETOH controls, and
increased PI uptake in 75 nM CP (p=.022) and 20 μM NMDA-treated slices (p<.001).
Among ETOH-naïve controls, increased uptake among 20 μM NMDA-treated (p<.001),
50 nM CP-treated (p=.003 ) and 75 nM CP-treated (p<.001) slices was noted. Figure 9
depicts PI uptake in the CA1, relative to controls.

Figure 9. CP-101,606 in CA1
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CA3
No effects of CP were noted in CA3. An overall ANOVA revealed a main effect
of TREATMENT, F(18, 193)= 8.864, p<.001, in CA3. No effect of sex was detected.
Planned comparisons (Fisher’s protected t) revealed fluorescence differences between
ETOH controls and ETOH+20 μM NMDA (p<.001), only. Among ETOH-naïve controls,
only increased uptake among 20 μM NMDA-treated slices (p<.001) was noted. These
results are depicted in Figure 10, below.

Figure 10. CP-101 in CA3
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DG
No effects of CP were noted in DG. An overall ANOVA revealed a main effect of
TREATMENT, F(18, 193)= 8.290, p<.001, in DG. No effect of sex was detected.
Planned comparisons (Fisher’s protected t) revealed fluorescence differences between
ETOH controls and ETOH+20 μM NMDA (p<.001), only. Among ETOH-naïve controls,
only increased uptake among 20 μM NMDA-treated slices (p<.001) was noted. These
results are depicted in Figure 11, below.

Figure 11. CP-101 in DG
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Figure 12. Representative Slices From Select Treatment Groups
including a) Control, b) ETOH, c) 20 μM NMDA, d) 50 μM JR-220 , e)
25 nM CP-101, and f) 20 μM MK-801 .
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OHSC Discussion
Results from the OHSC screen demonstrated the neuroprotective potential of both
compounds. Among cultures examined in the JR experiments, the untreated, ETOHexposed slices demonstrated increases in PI fluorescence of approximately 70% in CA1.
At all concentrations examined, JR-220 reduced fluorescence. Comparison among
ETOH-naïve slices indicated no associated toxicity in controls at any concentration of JR.
Results from the CA3 region were slightly perplexing; ETOH was associated with a
moderate increase in PI fluorescence. The lowest concentration of JR (50 μM) appeared
to reduce ETOH-associated toxicity; while 100 μM significantly increased it. This higher
dose was also associated with toxicity in ETOH-naïve cultures. A similar pattern of
effects were noted in DG, however only the increased toxicity among ETOH-naïve slices
treated with 100 μM JR retained significance. These results are somewhat perplexing, in
that JR did not appear toxic in the CA1, considered particularly sensitive to polyamines
and polyamine manipulation (Butler et al., 2010), but did appear toxic in less sensitive
regions. While these findings should be interpreted cautiously (given the low number of
subjects exposed to the 100 μM concentration), they may suggest additional mechanisms
of JR-220 action, and potentially an unanticipated toxic mechanism (discussed in greater
depth in the final discussion section).

Among cultures examined in the CP-101 experiments, the untreated ETOHexposed slices demonstrated increases in PI fluorescence of approximately 90% in CA1.
The results from CA1 were suggestive of a U-shaped curve; low doses (5 nM) were
ineffective at reducing toxicity, moderate doses (10 and 25 nM) were efficacious, while
higher doses (50 and 75 nM) indicated an exacerbation of toxicity. These effects were
mirrored in ETOH-naïve slices (50 and 75 nM concentrations increased fluorescence).
While the high selectivity of CP-101 is suggested to limit its inherent toxicity and side
effect profile, the NR2B class of NMDAr antagonists has been associated with toxic
effects in NR2B-rich nuclei (Parsons, Danysz & Quack, 1998). In contrast to those
cultures in which JR was examined, no ETOH-associated increases in CA3 or DG were
noted among control slices in these experiments. Furthermore, no evidence of CP-
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associated toxicity was noted among either ETOH-exposed or naïve slices in either CA3
or DG. The contrast between marked CA1 toxicity is likely due to the noted
concentration of NR2B subunits in CA1, and suggests low, if any, expression of
NR2B/2B stoichiometries in either DG or CA3.

These results are consistent with our hypotheses that inhibitory polyamine modulation,
whether NR2B-specific or not, would attenuate excitotoxic injury. The success of both
compounds in this screen (at multiple doses) indicated their potential for neuroprotection,
thus both compounds were advanced to simple behavioral screening.
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Experiment 2: Handling-Induced Convulsion (HICs)
Examining seizure-susceptibility in ETOH-exposed rodents via handling has been
used as a behavioral model of withdrawal severity for some time. The HIC procedure was
first developed by Goldstein & Pal (1971), and has been utilized by a variety of groups
since (e.g., Crabbe et al., 1980; Grant et al., 1990; Wilson & Little, 1998). HICs are
precipitated by removing the animal from its home cage by holding the tail, then gently
spinning it. HIC seizures are graded in their severity, producing a scorable response,
facilitating their use as both an indicator of CNS hyper-excitability and a sensitive
assessment tool. However, many HIC studies have used either extended periods of
exposure or ETOH inhalation chambers. The current experiment utilizes an abbreviated
procedure, designed to more efficiently screen compounds for anticonvulsant effects.
Instead of prolonged or inhalation exposure, our procedure utilizes an ETOH
dehydrogenase inhibitor (4-methylpyrazole; 4MP), administered concurrently with
ETOH. While pyrazole has been used in this manner previously (e.g., Terdal & Crabbe,
1994), our lab has demonstrated that with its use, convulsant activity may be precipitated
after only three days of i.p. ETOH exposure (Farook et al., 2007).

NMDAr antagonism induces known anticonvulsant effects during ETOH WD
(Rossetti & Carboni, 1995). Our abbreviated screening procedure has been validated with
numerous relevant compounds; reductions in HICs associated with acamprosate (Farook
et al., 2008), topiramate (Farook et al., 2007) memantine (Stepanyan et al., 2008) and
ifenprodil (unpublished data) have all been demonstrated. Moreover, while our screen
uses Swiss Webster mice, reductions in WD-associated seizures appear across other
strains/species (e.g., memantine; Bienkowski et al., 2001; Kotlinska, 2001).
Specifically, we hypothesized that following chronic ETOH+4MP treatments, JR and CP
would reduce withdrawal-associated handling-induced convulsion.
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Subjects
Male Swiss Webster mice (Harlan, IN) weighing 29±3 g (approximately 15-18
weeks) were housed 3/cage. A 16/8 light/dark cycle (on at 0600h, off at 2100h) and ad
libitum chow and water were maintained throughout the experiment. Thirty-five mice
were used per experimental replication, divided into 7 groups of 5 animals, each. Three
experimental replications were conducted for each drug tested.

ETOH & Drug Treatments
A 2.5 g/kg ETOH solution was administered (i.p.) daily (1300 h), using an
injection volume of 10 ml/kg, for three consecutive days. 4MP (9 mg/kg; Sigma-Aldrich,
USA), an ETOH dehydrogenase inhibitor, was co-administered with saline or ETOH. 10
h following the third and final administration of ETOH, animals were administered
treatment dissolved in saline and injected at 10 ml/kg (i.p.). Thirty minutes following
drug administration, animals were assessed for convulsive activity.

A range of JR-220 doses was examined in this paradigm; the first replication
utilized low doses (1-15 mg/kg), and when no obvious behavioral perturbances were
noted the dose was increased (10-40 mg/kg) for subsequent replications. Since we had
greater confidence in our selection of active doses for CP based on available animal
literature, all three replications utilized the same 1-20 mg/kg range.

HIC Scoring
Assessment of seizure susceptibility was performed by gently lifting each mouse
by the tail and observing convulsive behavior; if no convulsions were present, they were
precipitated by gently spinning the animals 360 degrees clockwise, then
counterclockwise, using the thumb and forefinger, for a period of 5 sec, after which
convulsions were assessed. Scoring was based on a modified scale (Wilson & Little,
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1998) and is described in Table 4. Scores indicated severity, with 0 indicating no
convulsive activity, 3 indicating clonic convulsion, and 4 indicating convulsion (prior to
spin) upon tail-lift. All scoring was conducted by an experimenter blind to treatment
condition.

Table 4. Handling-Induced Convulsion Assessment Scale

Blood Sampling
Blood samples were collected following the 3rd day of alcohol exposure and
analyzed using the Analox AM1 Alcohol Analyzer (Lunenberg, MA). Animals received
either ETOH alone or in combination with 4MP. Approximately 8 animals were used for
each treatment condition, divided into two groups, such that each group was sampled at
three exclusive time points (i.e. group 1 sampled at 30, 120, 480 min; group 2 sampled at
60, 240, 600 min). Blood was gathered by removing the tip of the tail (1 mm) and
collecting approximately 40 µL of tail blood in heparinized tubes. Tubes were
centrifuged and plasma frozen for analysis. Blood was collected at 30, 60, 120, 240, 480
and 600 min following injection, and again at 24 h. A separate group of animals were
used for the BEC analyses.
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Statistical Analysis
Each compound was analyzed in three experimental replications (N’s=105). HIC
scores were converted to a percentage of the ETOH-naïve group average, to reduce
variability and allow for comparison across replications. Scores were analyzed using oneway ANOVA (treatment). Post-hoc comparisons were conducted using Dunnett’s test,
comparing each group to the ETOH controls. BEC analyses were conducted using
repeated measures ANOVA, with 4MP exposure as the between-subjects variable.

Results: BECs
4MP increased BECs at two time-points. An initial repeated measures ANOVA
(4-MP x TIME) revealed an interaction of time and treatment. T-tests conducted at each
time point indicated significantly higher blood ethanol at 120 and 240 minutes following
injection (p’s <.001) showing the differential ethanol exposure caused by the addition of
4MP (or something to provide the reader with what it means in a simple sentence or
two). Blood ethanol in both groups was reduced to minimal levels by eight hours, postinjection. These results are depicted in Figure 13.
Figure 13. BEC as a Function of Time and 4MP Treatment
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JR-220 HICs
JR-220 reduced HIC behaviors at doses ranging from 10-40 mg/kg. HIC scores
from all three JR-220 replications were converted to percentages of the average control
group’s score, and combined into a single dataset. The ANOVA indicated a significant
effect of treatment, F(7, 79)= 4.297, p=.001. Dunnett’s tests detected differences between
ETOH controls and 10 (p=.019), 15 (p=.010), 20 (p=.001), 30 (p=.002) and 40 (p=.001)
mg/kg doses of JR-220. These results are depicted in Figure 14.

Figure 14. JR-220 HICs, Percent Control Values
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CP-101,606 HICs
CP-101 reduced convulsions at all doses tested. The ANOVA indicated an effect
of treatment, F(4, 90)= 15.444, p<.001. Dunnett’s tests indicated signficant reductions in
HICs for all doses of CP tested, including 1 (p<.001), 5 (p<.001), 10 (p<.001) and 20
(p<.001) mg/kg. Results are depicted in Figure 15.

Figure 15. CP-101,606 in HICs, Percent Control Values
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HIC Discussion
In the HIC tests, both compounds were found to be effective at reducing
convulsive behavior during ETOH withdrawal, across a range of doses. JR-220’s
attenuation of HICs was dose-dependent, with 1 and 5 mg/kg doses failing to
significantly reduce the behavior. However, the trend for reduction noted at 5 mg/kg and
the striking similarity in the means and SEs between the 5 and 10 mg/kg groups suggest
that the 5 mg/kg dose would have achieved significance had the subject representation
been equivalent across groups (5 mg/kg n=5; 10 mg/kg n=15).

Prior to analyzing compounds in this screen, BEC curves were generated to establish 4MP’s elevation and potentiation of ETOH in blood. While a clear increase in peak BEC
was noted following 4MP, as was an increase at the 4 hr measurement, increases in the
duration of detectable ETOH in blood may be inferred due to the linear metabolism of
ETOH (but are not directly demonstrated in this experiment); BECs returned to 0
between our 4 and 8 hr measurements. Importantly, 4MP has been tested in ETOH-naïve
animals, with no discernable effect on HIC scores (Farook et al., 2007).

CP-101,606 appeared to dose-dependently reduce HICs at every dose tested,
demonstrating slightly higher potency relative to JR. This is not surprising, when
efficacious concentrations in the OHSC experiment are considered (10 & 25 nM CP vs.
50-125 mM JR). The magnitude of CP effects at equivalent doses also appeared greater.
However, NR2B-containing NMDArs are thought to uniquely contribute to
seizure/convulsive behaviors, and the implication of NR2B involvement in excitotoxicity
(thought to underlie convulsive behavior) is well established. Thus, CP’s potency should
again be unsurprising. While the data are not presented in the current work, CP’s potency
appeared approximately equivalent to that of the NR2B-specific antagonist ifenprodil.
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A parsimonious interpretation of these results suggests that ETOH WD-associated
seizure susceptibility is under at least partial control by NR2B subunits. Speculatively,
the observed reductions in convulsive behavior, which at higher doses of both
compounds were well below that of the ETOH-naïve animals, corroborates evidence that
NR2B antagonists have potent anticonvulsant potential (e.g., Wlaz et al., 1999), and
suggests that JR-220 shares agmatine’s noted anticonvulsant properties (Feng et al.,
2005). The success of both compounds in this screen provide further (albeit indirect)
evidence for neuroprotection. Taken together, OHSC and HIC results suggested that both
compounds possessed the potential to blunt withdrawal effects and protect from
withdrawal-associated damage.
These results support the hypothesis that inhibitory polyamine modulation will reduce
withdrawal-associated handling-induced convulsion.
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Experiment 3: Conditioned Pseudo-Withdrawal in the Elevated Plus Maze (EPM)
Opponent-process theory, mentioned in previous sections, conceptualizes drug
effects (a-processes) as being mediated by compensatory physiological responses
designed to maintain homeostasis (b-processes). Following chronic use, it is hypothesized
that b-processes are induced by drug-associated cues and are thought to trigger drugopposite effects similar to withdrawal, increasing the negative reinforcing value of the
drug and potentially leading to resumption of use. One important capability of potential
anti-relapse treatments, therefore, is the ability to blunt responses to drug-associated cues
during acute and protracted withdrawal.

While several relapse models have utilized ETOH-associated conditioned cues,
the behavioral responses of interest are generally consummatory in nature, and therefore
unable to answer questions about inhibition of ETOH-conditioned behavior, since the
reinforcing effects of ETOH confound interpretation. The current screen was developed
as a solution, and involves repeated pairing of ETOH with an ETOH-associated
environment (an elevated-plus maze; Cole et al., 1999). Following repeated ETOH-maze
pairings, a vehicle injection appears to induce conditioned abstinence behavior. This
behavior is not elicited when the vehicle injection is delivered in a non-conditioned
environment, when ETOH is on board, or when previously ETOH-naïve animals are
administered ETOH in the plus maze. The primary abstinence behavior is termed
‘stretched-attend’ posture, and involves extension of the forepaws and upper body
(“stretch”), without forward movement. An alternate interpretation of this behavior is that
it could indicate cued behavior resulting from positive interoceptive or internally
rewarding feelings (an ‘incentive salience’ interpretation, rather than an ‘opponentprocess’ interpretation), indicating pleasure derived from the conditioned stimulus.
However, when naltrexone was examined in this model, no attenuation of the stretchedattend behavior was noted (Cole et al., 2000). In contrast, acamprosate (thought to relieve
negative affect) was effective in reducing these behaviors (Cole et al., 2000), suggesting
their association with negative affect or conditioned withdrawal. The demonstration of
acamprosate’s efficacy in this model suggests strong predictive validity for its use as an
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anti-relapse screen. Furthermore, while potentially any novel environment could be
conditioned in this manner, the use of the elevated plus maze (EPM) allows for the
additional examination of secondary effects of the compounds, including the examination
of exploratory and anxiety-related behaviors.
Specifically, we hypothesized that JR would reduce stretched-attend responses to an
ETOH-conditioned environment (the elevated plus maze).

Apparatus
The EPM was constructed from black Plexiglas, with two arms enclosed by walls
(30 x 17 x 6 cm) and two open (unprotected) arms (30 x 6 cm). The maze was elevated
44.5 cm above the floor.

Procedure
Mice were divided into 4 groups (n’s=5-6) in which 2 groups received saline and
2 received i.p. ETOH injections (1.75 g/kg). Animals were injected daily for 9 days,
between 1200h and 1300h. 10 min after injections, they were placed on the center of the
plus maze test apparatus for a 5 min conditioning session (Cole et al., 2000; Farook et al.,
2007). On day 10, subjects received either saline or a 20 mg/kg dose of JR. A 40 mg/kg
group was also included, however the generated data were not interpretable due to
sedative effects and thus were removed from the dataset; see discussion for further
details. Thirty minutes following injection they were then placed in the center of the
maze. On day 10, behavior in the maze was recorded for a 5 min test session. The
dependent variables included time spent in the open vs. closed arms, total number of arm
entrances and number of stretched-attend postures (defined as when the subject stretches
forward with its forepaws without actually moving its hind paws) (Cole et al., 1999,
2000; Farook et al., 2007). An arm visit was defined as all four paws in one arm.
Behavior was recorded using a tripod-mounted video recorder (SONY). An experimenter
remained in the room but was screened from the animals’ view.

70

Analysis
For each dependent variable a 2 x 2 ANOVA (ETOH Exposure x Treatment) was
conducted. Post hoc tests (Fisher’s protected t) were conducted to further explore
significant effects.

Results
JR-220 reduced stretched-attend posture in ETOH and saline-treated animals. A 2
x 2 ANOVA for stretched-attend behaviors revealed main effects of both pretreatment
and JR treatment. Pretreatment with ETOH was associated with increased stretchedattends, F(1,20)=33.665 p=.029, while JR treatment was associated with reductions in the
behavior, F(1,20)=29.106 p=.002. Post hocs revealed that among JR-naïve animals,
ETOH pre-exposure was associated with increases in stretched-attends, relative to saline
(p=.001). JR-associated reductions were evident among both saline (p<.001) and ETOHpretreated controls (p<.001). These differences are depicted in Figure 16.
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Figure 16. Stretched-Attend Behaviors

JR-220 was associated with increases in closed-arm occupancy and reduction in
open-arm occupancy. A 2 x 2 ANOVA conducted for time spent in closed arms detected
a main effect of JR, such groups receiving JR spent greater time in the closed arms of the
maze, F(1,20)=7.425 p=.014. Post hoc tests revealed that the significance of this effect
persisted for saline pretreated animals (p=.016), but was not significant for the ETOHpretreated animals. Identical analyses were conducted for time spent in open arms; a
significant main effect of JR, such that JR treatment reduced time spent in open arms,
was detected, F(1,20)=10.282 p=.005. Again, this effect was significant among salinepretreated animals, but not ETOH animals. These results are depicted in Figure 17, with
the scales being made equal to facilitate direct comparison between the variables.
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Figure 17. Time Spent in Closed vs. Open arms

JR-220 was associated with hypoactivivity in saline-treated animals. A 2 x 2
ANOVA for total arm entries revealed main effects for both pretreatment and JR
treatment. Pretreatment with ETOH was associated with increased arm entries in the
maze, F(1,20)=5.672 p=.029, while JR treatment was associated with reductions in
entries, F(1,20)=13.859 p=.002. Post hocs revealed that JR-associated reductions in
activity persisted only among saline-treated animals (p=.004), although the reduction
approached significance among ETOH-treated animals (p=.07). These results are
depicted in Figure 18.
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Figure 18. Total Arm Entries

EPM Summary
The primary measure of interest in the cue-conditioned EPM screen was
stretched-attend postures, thought to index conditioned withdrawal behavior. ETOHexposed animals produced a greater number of stretched-attends in the conditioned
environment, relative to controls. Stretched-attends in this group were significantly
reduced following a 20 mg/kg dose of JR-220. While this action is consistent with our
hypothesis, JR’s action in ETOH-naïve animals provided some interpretational difficulty;
JR reduced stretched-attends significantly, and with a similar magnitude as was noted for
ETOH-exposed animals.

One possible interpretation would indicate a generalized anxiolytic effect.
Agmatine (of which JR-220 is an analogue), as well as a number of compounds which
would be hypothesized to produce agmatine-like action (including L-arginine, DFMO,
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aminoguanidine and arcaine) are known to reduce ETOH-associated withdrawal anxiety
in the EPM (Taksande et al., 2010), consistent with the hypothesis of a generalized
anxiolytic effect. However this anxiolytic action would be atypical, as open-arm dwelltime was reduced by JR (and closed-arm dwell-time increased) among the ETOH-naïve
group. Generally, this closed-arm preference would be interpreted as evidence of an
anxiogenic action.

It is also possible that reduction in stretched-attends was due to a generalized
hypoactivity induced by JR, an interpretation consistent with the noted reduction in arm
entries among ETOH-naïve animals and the trend (p=.07) toward a reduction in ETOHexposed animals. This interpretation is also supported by the effects of the 40 mg/kg JR
dose in this paradigm (data not shown). The 40 mg/kg dose resulted in complete
immobility in a subset of animals, precluding any interpretation of stretched-attend
behaviors, and thus this data was discarded.

While JR’s effects in this screen were equivocal, reductions in stretched-attend
behavior among ETOH-exposed animals at least suggested the potential to reduce
ETOH-associated cues. Thus, when considered in light of its efficacy in previous
experiments, JR was advanced to the more complex behavioral screens. However, we
decided that analyzing JR’s effects on activity in a more direct manner would be prudent
(activity data are presented below in Experiment 7).
Although results are consistent with the hypothesis that JR would reduce stretchedattends, however they add little additional support, considering noted interpretational
issues.

75

Experiment 4: Alcohol Deprivation Effect
The alcohol deprivation effect (ADE) refers to temporary increases in ETOH
consumption, compared with baseline conditions, when ETOH is reinstated following a
period of forced abstinence (Sinclair & Senter, 1967). The ADE is thought to indicate
relapse-like behavior (Spanagel et al., 1996). The phenomenon is noted across several
species, including rats (e.g., Vengeliene, 2003), mice (e.g., Salimov et al., 1993), nonhuman primates (e.g., Kornet et al., 1990) and humans (Burish et al., 1981; Mello &
Mendelson, 1972). Adding to its face validity to human relapse, the ADE phenomenon is
noted to occur following short deprivations (e.g., 12 h; Sinclair & Li, 1989) as well as
following an extended abstinence period (75 d; Sinclair et al., 1973).

Interestingly, alcohol preference among rodents appears relatively unrelated to
their propensity to display an ADE (for review see Rodd et al., 2004). While the alcoholpreferring (“P”) rats display robust ADE behaviors, the Alko Alcohol (“AA” line) rats
only display short term (12 and 24 h) ADEs (Sinclair & Li, 1989); Sardinian alcoholpreferring (“sP” line) rats do not display ADE behavior (Agabio et al., 2000); and high
alcohol drinking (“HAD” line) rats display ADE only under certain conditions (RoddHenricks et al., 2000). Vengeliene and colleagues examined these preferring lines with
Wistar rats (2003) and found ADE behavior only in the P and Wistar animals. However,
the majority of this work examines ADE following only the first deprivation period.
When repeated deprivation periods are used, ADE behaviors in preferring lines (e.g.,
HAD rats) which are not immediately evident initially, can emerge (Rodd-Hendricks et
al., 2000). Similarly, in animals which do display initial ADE behaviors, repeated
deprivation cycles can markedly increase intake; one study demonstrated 16 g/kg
consumption during the 24 hr following reinstatement in P-rats (Li et al., 1993).

Taken together, these findings suggest that relapse-like behavior thought to be
modeled in the ADE paradigm may reflect pathophysiological changes occurring during
chronic consumption and abstinence, rather than the positive reinforcing value of ETOH
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or initial ETOH preference. However, the noted ability of naltrexone to reduce ADE
behavior (Heyser, Moc & Koob, 2003; McBride, Le & Noronha, 2002) suggests that the
behavior is still under at least partial control of the positively reinforcing value of ETOH
following reinstatement. While the mGLUr antagonist, MPEP, reduces ADE behavior
(Backstrom et al., 2004), the efficacy of acamprosate in this paradigm (Vengeliene et al.,
2010; McBride, Le & Noronha, 2002) is of greatest relevance to the current work, and
suggests the predictive validity of our ADE procedure.

Although described in detail below, our modified ADE screen uses SpragueDawley rats, which do not readily acquire significant ETOH self-administration. Thus,
we employ a sucrose-fading procedure to train drinking. Animals undergo at least three
reinstatement periods after deprivation. The first is an untreated period to verify that the
deprivation effect is detectable. The second and third reinstatements are conducted
following treatment with either the compound of interest, or vehicle, in a within-subject
manner (with treatment order balanced across groups). This procedure allows us to
efficiently and reliably produce ADE behavior in Sprague-Dawleys following less than
one month of ETOH exposure.
Specifically, we hypothesized JR-220 would attenuate increases in consumption following
ETOH reinstatement, relative to baseline levels.

Subjects
Subjects were male Sprague-Dawley rats individually housed in plastic cages in a
temperature-controlled colony room (70°±2 F) on a 12h light-dark cycle, with food and
water provided ad libitum.
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ADE Procedure
Male Sprague-Dawley rats were trained to consume ETOH using a sucrose-fading
procedure, which entailed gradually replacing the sucrose in a 10% solution with ETOH,
until animals were consuming a sucrose-free 12% ETOH solution. Free access to water
was maintained throughout the experiment in one drinking tube, while varying solutions
of sucrose and ETOH were provided in the other. The sucrose fading schedule is
presented in Table 5.

Table 5. Sucrose Fading Schedule
Phase

Solution

Days 1-3

Water in both bottles

Days 4-6

One bottle replaced with 10% sucrose

Days 7-9

10% sucrose / 3% ETOH

Days 10-12

10% sucrose / 6% ETOH

Days 13-15

10% sucrose / 9% ETOH

Days 16-18

10% sucrose / 12% ETOH

Days 19-21

5% sucrose / 12% ETOH

Days 22-27

12% ETOH

Ethanol consumption during the last 3 days of 12% ETOH access was averaged
and used as a baseline for comparison with post-deprivation consumption. Following the
sucrose-fading procedure, ETOH deprivation/reinstatement cycles began. Each
reinstatement period lasted for 72 hours. Deprivation periods were varied at 4±1 days, to
insure that the animals did not adapt to a schedule. All animals received a single (nondrug treated) reinstatement cycle to assess elevations in drinking compared to baseline.
During the following reinstatement period animals were randomly divided into treatment
groups, receiving either drug or saline. Two experiments were conducted (each
examining a different dose of JR); separate animals were used for each. An initial
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experiment examined a 20 mg/kg dose (n=54), followed by a smaller-scale experiment
examining 10 mg/kg (n=13) designed to alleviate interpretational issues concerning
general fluid consumption. Injections were administered (i.p.) 30 minutes prior to ETOH
reinstatement, and then repeated daily for the duration of the treatment phase. The
dependent measure was ETOH consumption (g/kg BW).

Analysis
Paired-samples t-tests were used to compare g/kg ETOH consumption during
each day of the ADE phase with baseline drinking. Total fluid consumption was also
analyzed in this manner. Paired-samples t-tests were further utilized to disambiguate the
direct effects of JR, as compared to saline, on water consumption.

Results
20 mg/kg JR
20 mg/kg JR appeared to both attenuate ADE behavior, and reduce consumption
on days 2 and 3. Paired sample t-tests revealed that following a deprivation period, the
animals consumed significantly more ETOH following reinstatement, compared to their
baseline drinking. A similar pattern as described above was observed, with increased
consumption on day 1, t(53)=3.890, p<.001, and day 2, t(53)=3.087, p=.003. Following
treatment with JR-220, day 1 consumption did not differ from baseline, however
consumption was reduced on day 2, t(53)=2.693, p=.010, and day 3, t(53)=4.164, p>.001.
Animals which received saline consumed significantly more on day 1, t(53)=5.170,
p>.001 and 2, t(53)=2.643, p=.011, relative to baseline. ADE phases compared with
baseline drinking are depicted in Figure 19.
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Figure 19. 20 mg/kg JR in ADE

No differences in water consumption were associated with the untreated
reinstatement phase, however both JR-220 and saline injections were associated with
reductions in water consumption during all injection days. In order to examine whether
JR-220 was associated with reductions in water consumption compared to saline controls,
a secondary set of paired-samples t-test was employed to compare these groups. Water
consumption was reduced by JR during day 1 t(53)=3.673, p=.001, and day 2,
t(53)=2.423, p=.019, but not day 3 of reinstatement. These results are depicted in Figure
20.
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Figure 20. Water Consumption in ADE Reinstatement Phases (20 mg/kg).

10 mg/kg JR
10 mg/kg JR appeared to attenuate ADE behavior. Paired samples t-tests revealed
that following a deprivation period, the animals consumed significantly more ETOH
following reinstatement, compared to their baseline drinking. This increase persisted for
both day 1, t(12)=3.084, p=.006, and day 2, t(12)=2.397, p=.034. Animals which received
saline consumed significantly more on day 1 of the drinking phase, t(12)=3.841, p=.002.
During the treated ADE phases, 10 mg/kg JR treatment appeared to attenuate increases in
consumption. ADE phases compared with baseline drinking are depicted in Figure 21.
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Figure 21. 10 mg/kg JR-220 in ADE

A second set of t-tests were performed to examine the effects of JR on water
consumption during reinstatement. No differences in water consumption were associated
with the untreated reinstatement phase, or treatment with JR-220. However, water
consumption on the first day of reinstatement was significantly lower among animals
administered saline, relative to baseline drinking. These results are depicted in Figure 22.
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Figure 22. Water Consumption During ADE Reinstatement Phases (10 mg/kg)

ADE Summary
Using a modified procedure designed to facilitate efficient drug screening, we
demonstrated that Sprague-Dawley rats with less than a month of exposure to ETOHcontaining solutions will substantially increase ETOH drinking behaviors following a
period of forced abstinence. This is notable both for the relatively short pre-deprivation
drinking period, as well as the rat strain used, as Wistar or various selectively bred lines
are used most commonly in this procedure. Additionally, one advantage of our screening
procedure is the relatively high levels of consumption it produces, ranging from 6-9 g/kg
during the first 24h following reinstatement, which contributes to the face validity of the
screen. Our observed levels of consumption are greater than is generally found in other
works (with several notable exceptions involving P-rats), however, the inclusion of a
sucrose fading procedure to accelerate ETOH consummatory behavior also raises the
possibility that consumption is being partially driven by previous associations with
sweetness/calorie content. While this complicates interpretation somewhat, it does not
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necessarily subtract from the face validity of the screen, as initiation of ETOH
consumption in humans rarely involves high ETOH/low carbohydrate solutions.

JR-220 administration at both 10 and 20 mg/kg doses attenuated the ADE,
reducing post-reinstatement consumption to control levels (or below). Paired-samples ttests indicated that following the 10 mg/kg dose, consumption levels during all treatment
days were indistinguishable from control levels, compared to saline treatment, in which a
significant day 1 increase was noted. Furthermore, the 10 mg/kg dose was not associated
with any reduction in water consumption. Saline-treated animals displayed reduced water
consumption during day 1, however this was most likely do to their preference for the
ETOH solution.

20 mg/kg administration of JR was also associated with a reduction in ADE
behavior. Following reinstatement, no increases in ETOH consumption relative to control
were noted in the first 24 h of access, in contrast to the significant increase in day 1
consumption among vehicle-treated animals. Interestingly, while animals treated with 10
mg/kg JR were no different from controls on any of the treatment days, 20 mg/kg JR was
associated with reductions in drinking on days 2 and 3. However, this is consistent with
the hypothesis that JR is capable of reducing a number of ETOH-associated behaviors,
including relapse (ADE day 1 consumption), and general reductions in consumption,
reflecting reduced reinforcing value. Reductions in water consumption during the treated
ADE phase were noted. While some reduction is expected due to the hydrating capability
of the injections (injections contained 2.5-5 mL saline, depending on body weight), direct
comparison of the saline and JR-220 treatments indicated a significant reduction in water
consumption associated with JR. Since saline treated animals demonstrated greater
preference for the ETOH solution, yet still consumed more water than JR-treated animals,
this is unlikely to be an artifact. The most likely possibilities for this noted reduction in
water include general reductions in the reinforcing value of natural rewards or a general
reduction in activity levels (including normal drinking behavior). The former possibility
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is unlikely, as JR has been directly examined in other drinking paradigms and found not
to affect water consumption (Justin Rhodes, personal communication). Furthermore, the
10 mg/kg dose was associated with reductions in ETOH but not water consumption,
arguing against a generalized reduction in reinforcement. Thus, JR’s potential effects on
activity remained a concern and were consequently examined in Experiment 7.

CP was not examined in this screen due in part to limited resources, and in part
because NR2B antagonism has been examined previously in the ADE paradigm; the
NR2B antagonist ifenprodil dose dependently reduces ADE behavior (Vengeliene et al.,
2005). Thus, while CP’s efficacy would have been noteworthy due to the noted
differences in its binding profile, the recognition of NR2B antagonist efficacy in this
paradigm influenced our decision to prioritize its examination in behavioral paradigms in
which NR2B involvement is less well-established (i.e., binge drinking).
Taken together, these results supported the hypothesis that inhibitory polyamine
modulation has the ability to attenuate reinstatement-associated increases in ETOH
consumption. Attenuation of relapse behavior in this experiment was encouraging,
however this paradigm lacks a major component associated with human relapse: stress.
Thus, we advanced JR to Experiment 5, examining its effects in chronically stressed
animals.
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Experiment 5: Stress-Associated Drinking
It is well known that stress increases alcohol consumption in a variety of species,
and is thought to be a primary contributor to relapse behavior in humans. Thus, we
included a stress-related paradigm into our screening hierarchy. A variety of stressors are
known to increase drinking behaviors in rodents, including foot-shock (e.g., Matthews et
al., 2008), social isolation (e.g., Nunez et al., 2002) and restraint/immobilization (e.g.,
Farook et al., 2009). C57BL/6J mice are known to readily consume ETOH, and their
consumption is both increased following stress challenge (e.g., Boyce-Rustay, 2008) and
sensitive to such factors as quality, severity, duration and frequency of stress. We
therefore used this strain in a simple restraint-stress procedure to screen for the ability of
our compounds to reduce stress-associated consumption.

Unfortunately, the literature involving GLUergic manipulations of stressassociated drinking is limited. There is some evidence suggesting acamprosate has the
ability to reduce stress-associated increases ETOH consumption (Füllgrabe, Vengeliene
& Spanagel, 2007), however these findings were age and sex-specific. Clinically,
acamprosate appears anxiolytic (Schwartz et al., 2010), and in a sample of patients
comorbid for anxiety and alcohol misuse disorders, reduced both anxiety symptoms and
alcohol use (Schwartz, Chilton & Aneja, 2007). These findings suggest compounds with
‘acamprosate-like’ action will positively modulate alterations in drinking behavior
resulting from stress, despite the paucity of available preclinical examinations involving
NMDAr manipulation.

While acamprosate has not yet been examined in this restraint-stress procedure, a
previous study conducted by our group using topiramate (Farook et al., 2009) suggests
that restraint elevates drinking behavior, and that such elevation may be moderated by the
‘acamprosate-like’ action of topiramate. While the screen presented below was designed
in a highly similar manner to that described by Farook (2009), the size of the unrestrained
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group was substantially reduced in order to increase efficiency and throughput, and only
saline and a single dose of JR was examined in controls.
Specifically, we hypothesized that stress-induced increases in ETOH consumption would
be attenuated following JR-220 administration.

Subjects
Male C57BL/6J (n=28) mice weighing 29±2 g (15-18 weeks old; Jackson
Laboratory, Bar Harbor, ME) were singly housed in standard polycarbonate cages with
corncob bedding. Chow and water were provided ad libitum.

Procedure
Prior to the start of an experiment, C57BL/6J mice were allowed to adjust to the
colony room for a period of 7 days, following shipment. Afterwards, water and ETOH
were available in feeding tubes (Dyets Inc., PA) inserted directly into the animal cage.
During the course of 7 days, the concentration of ETOH was gradually increased from
3% (days 1-2) to 6% (day 3-5) to 12% (days 6-7). Drinking tube position was alternated
daily in order to avoid any positional bias. Water and ETOH consumption were measured
daily, throughout the experiment.

At the start of the restraint phase, mice were divided into groups; 20 animals
received restraint, with 8 controls. Restraint was performed daily, for 5 days, by placing
mice into transparent plexiglass restraint chambers (10 cm x 4.5 cm x 3.2cm) for one
hour. Unrestrained animals were handled briefly, then transported in their home cage to
the restraint room and left for one hour. Restraint was ceased after 5 days (prior to the
first day or treatment). Animals exposed to the restraint stress were subdivided into four
groups (n’s=5), each receiving 0, 10, 20 or 30 mg/kg JR-220. Unrestrained animals were
divided into two groups (n’s=4), receiving saline injections or the high dose (30 mg/kg)
of JR-220. Injections were repeated, daily, for five days, post-restraint.
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Statistics
An initial repeated measures ANOVA (group x day) was performed between
unrestrained controls and restrained animals, to assess the effects of daily restraint on
ETOH consumption. Following restraint, the multiple doses of JR were analyzed using a
two-way repeated measures ANOVA (Dose x Day). Additional ANOVAs, and
subsequent post hocs (Fisher’s protected t) were conducted to further examine significant
effects, where appropriate.

Results
Restraint stress was associated with increases in ETOH consumption. A group x
day RM ANOVA detected a main effect of group, revealing that ETOH consumption was
increased among animals undergoing restraint, F(1, 26)=122.479, p<.001. Additionally, a
significant interaction between group and day was noted F(1, 26)=6.773, p=.015. Thus, ttests were conducted between groups for each day, individually. In all cases a significant
difference between groups was detected (p<.001, p=.001, p<.001, p<.001, p<.001, for
days 1-5, respectively). Graphing the interaction (Figure 23) suggests divergence of
ETOH consumption over time, in a group-dependent manner. Consumption among
restrained animals increased over time, while unrestrained animals’ consumption
decreased over time.
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Figure 23. Restrained vs. Unrestrained Drinking

Following the 5-day restraint phase, restrained animals were administered one of
four doses of JR (0, 10, 20, 30 mg/kg), daily, and allowed to consume ETOH freely for
an additional 5 days. JR administration reduced drinking in a time-dependent manner. An
initial RM ANOVA detected an interaction between day and dose, F(12, 64)=2.186,
p=.023, thus, individual ANOVAs were conducted for each day, individually. No effect
of dose was noted for days 1 or 2, however by day 3 dose emerged as significant,
F(3,19)=10.958, p<.001, and remained significant during day 4, F(3,19)=21.722, p<.001,
and day 5, F(3,1)=8.636, p<.001. Fisher’s post hocs were performed for days 3-5. During
day 3, saline treated animals consumed significantly more ETOH than 10, 20, or 30
mg/kg JR-treated animals (p=.008, p<.001, p<.001, respectively). On day 4, salinetreated animals again consumed significantly more ETOH (p=.006, p<.001, p<.001,
respectively), however the animals exposed to 30 mg/kg also consumed less than animals
receiving either 10 or 20 mg/kg JR (p<.001, p=.008, respectively). On day 5 JR-treated
animals again consumed less than saline-treated (p=.010, p=.003, p<.001, respectively),
although among JR-treated animals consumption did not differ as a function of dose.
These results are depicted in Figure 24, below.
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Figure 24. JR-220 Treatment (Following 5-day Restraint Period)

Additional analyses were conducted on animals which received no exposure to
the restraint paradigm, but were treated with either saline or the highest (30 mg/kg) dose
of JR-220. An RM ANOVA (treatment x day) was conducted, however no main effects
or interactions were noted.

Since the investigation of JR in unrestrained animals was not a primary focus of
this experiment, sample size for this analysis was low (n’s=4). Thus, we were concerned
that the (treatment x day) RM ANOVA lacked sufficient power to detect differences on
individual days. We therefore chose to examine the final day of treatment (Day 5), using
a t-test. 30 mg/kg JR appeared to reduce Day 5 consumption, t(6)=2.900, p=.033, despite
the lack of an overall (treatment x day) interaction (depicted in Figure 25). While the t
value for this analysis was modest, the low n’s suggested a sizeable effect. The effect size
for the 5th day was found to be a “large” effect (Cohen’s d=2.37).
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Figure 25. Unrestrained Animals, 0 vs. 30 mg/kg JR

Restraint Stress Summary
Prior to drug treatment, daily restraint stress induced elevations in ETOH selfadministration. The primary measure of interest in this screen was alterations in ETOH
self-administration following chronic stress. At all three doses examined (10, 20, 30
mg/kg) JR-220 was capable of reducing consumption. However, the temporal pattern of
this reduction was particularly interesting; during the first 2 days of JR administration no
differences were detectable, and it was only during the 3rd, 4th and 5th days of ETOH
consumption that such differences emerged. However, this is not a unique pattern.
Previous use of this procedure (Farook et al., 2009) produced a similar pattern of results,
with significant differences between treated and un-treated groups not emerging until the
last half of the treatment phase. One interpretation of such delayed efficacy would
suggest that both compounds require several days for concentrations to reach maximally
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effective levels. While the 21 h half-life of topiramate (Bialer, 1993) is consistent with
this interpretation, no data is currently available concerning metabolism of JR-220. An
alternative interpretation is that dysregulation of HPA function and resultant negative
affect are not immediately reversible, but rather need some time to ‘balance’ or ‘downregulate’.

However, while patterns of slow-onset efficacy in restrained animals are similar
between studies, the patterns of ETOH consumption during the restraint phase, and the
magnitudes of consumption in both restrained and non-restrained animals appear
markedly different when the current project is contrasted with the topiramate study.
Consumption among restrained vs. unrestrained animals in the topiramate study increased
from ~10 to ~19 g/kg and ~7.5 to ~12.5 g/kg in restrained and unrestrained animals,
respectively; the current study observed only a slight increase associated with restraint
(~9 to ~11.5 g/kg), and a decrease (~6 to ~4 k/kg) in unrestrained animals. Since both
sets of experiments employed nearly identical methodologies, such differences are
puzzling. However, the overall findings from both studies, that restraint-associated
increases in consumption may be attenuated in a time-dependent manner via GLUergic
modulation, are consistent.

The inclusion of unrestrained controls in this paradigm was primarily to insure
that restraint stress resulted in increased consumption, however following the restraint
phase this group allowed for the additional examination of JR in unrestrained animals. A
JR-associated reduction was noted, however only after several days of treatment (similar
to the restrained animals). Finally, the large effect size of the Day 5 difference suggests
the reliability of this finding, even with unfortunately low n’s.
These results were consistent with our hypothesis that inhibitory polyamine modulation
would reduce stress-associated ETOH consumption.
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Experiment 6: Drinking in the Dark (Screen)
As noted previously, the C57BL/6J mouse is considered an alcohol-preferring
strain. However, among C57s, other mouse strains, or other species, it has been
(historically) difficult to produce binge-like self-administration to the point of behavioral
intoxication. For instance, while C57s will take nearly all daily fluid intake from a 10%
ETOH solution in a 2-bottle choice, 24 h access paradigm, measurable effects on
physiology and/or behavior are lacking and pharmacologically significant BEC levels are
not maintained (Dole & Gentry, 1984). Although some noted exceptions exist (e.g.,
Middaugh et al., 1999; Ryabinin et al., 2003), these and other binge models generally
involve extended periods of previous administration, stress (or other environmental
manipulation, e.g., food deprivation) or previous forced administration (e.g. ETOH vapor
inhalation chambers). While operant techniques are able to avoid many of these pitfalls
(e.g., Roberts, Heyser & Koob, 1999), the procedures require significant individualized
training over time, and are thus ill-suited for high-throughput screening.

Fortunately, a limited-access procedure which involves neither food nor water
restriction, and leads to pharmacologically significant levels of consumption, has recently
been established. Rhodes and colleagues (2005), in a methodologically rigorous
examination, described the tendency of C57BL/6J mice to consume significant quantities
of alcohol under limited-access conditions (2-4 hours) during their active (dark) cycle,
termed ‘Drinking in the Dark’. Under these conditions the mice are known to consume
high concentrations (20%) of ETOH to the point of intoxication with BECs as high as .16
g/dl (Rhodes et al., 2005). Furthermore, several behavioral indices of intoxication are
noted, including impaired performance on the accelerating rotarod and balance beam tests
(Rhodes et al., 2007) and gait abnormalities (Rhodes et al., 2005). Finally, the
establishment of such high levels of consumption requires few days of ETOH experience,
and may be generated within 1-2 weeks. This DID procedure thus provides a simple
binge model with high face validity which is particularly well suited to genetic and
pharmacological investigations.
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The predictive validity of this model has been established using a number of
compounds. The binge-like nature of DID behavior and the short amount of time required
to establish it, suggest that in this particular model consumption may be driven largely by
positive reinforcement. The effects of VTA micro-injection of baclofen (Moore &
Boehm, 2009), as well as systemically administered naltrexone (Kamdar et al., 2007), are
consistent with this hypothesis. However, GLUergic manipulations also appear to reduce
consumption; both MPEP (an mGLUr inhibitor) and acamprosate significantly and dosedependently reduce the behavior (Gupta et al., 2008). Interpretation of such efficacy is
equivocal; these GLUergic compounds may serve to reduce positive reinforcement, or,
despite short onset of the binge-like behavior, it may still be partially driven by the
negatively reinforcing value of ETOH.

The experiments presented below are DID screens which were adapted from
Rhodes and colleagues (2005). While the basic methodology was retained, treatment
schedules differed (allowing us to assess prolonged effects of treatment on ETOH
consumption the day following treatment) and dose ranges were more limited (to
facilitate higher throughput). Unlike many of the aforementioned screens, this procedure
was novel for our lab at the time of JR and CP testing, thus we included acamprosate in
these initial experiments to further the establishment of the screen’s predictive validity.

We hypothesized that the high levels of ETOH consumption noted during brief periods of
dark-cycle access to ETOH would be reduced by inhibitory polyamine modulation via JR
and CP.

DID (Screen) Subjects
Male C57BL/6J (N=20) mice weighing 30±3 g (15-18 weeks old; Jackson
Laboratory, Bar Harbor, ME) were singly housed, in a room maintained on a 12:12
reversed light/dark cycle, with lights turned off at 0600 h and on at 1800 h EST. Red
incandescent lamps were used during feeding, cage-changing and testing to avoid
circadian disruption. Animals were housed in standard polycarbonate cages with corncob
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bedding. Rat chow and water were provided ad libitum, except when ETOH was
substituted for water.

DID (Screen) Procedure
Upon arrival, animals were habituated to the colony room for seven days. Twenty
percent ETOH solutions were prepared daily. ETOH solutions were delivered in 10 ml
graduated cylinders, fitted with double ball bearing sipper tubes (to prevent leakage).
ETOH access was initiated 4 hr into the dark cycle. This was done in the home cage,
where animals were singly housed. The cylinders remained in place for 4 hrs, after which
cylinders were removed and water bottles re-introduced.

A three week (5 days/week) period ETOH exposure was conducted prior to drug
treatment. Each animal received all compounds tested, in a counterbalanced, latin-square
design (Figure 26). ETOH consumption was allowed each day preceding and following a
treatment. Screen 1 examined saline, 10 mg/kg JR and 10 mg/kg CP. Screen 2 examined
saline, 300 mg/kg acamprosate, and 20 mg/kg JR. Doses were selected based on efficacy
in previous experiments and/or selected from the literature. Figures 27 and 28 depict the
treatment schedule and consumption prior to treatment exposure, respectively.

Figure 26. Latin-Square Design for Screen 1 and Screen 2
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Figure 27. DID ETOH Access Schedule (Single Phase; Dark/Light Boxes Indicate
ETOH/Water, Respectively)

Figure 28. Daily DID Consumption (4 hr/day) Prior to Treatment Phase
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DID (Screen) Results
Data were analyzed with paired-samples t-tests, comparing treatment groups to
controls. An alpha of .05 was used for both phases of the experiment. In screen 1, ETOH
consumption was significantly reduced following CP treatment, compared to saline,
t(19)=3.483, p=.002. Likewise, JR-220 treatment significantly reduced consumption,
t(19)=4.041, p=.001. These results are presented in Figure 29.

Figure 29. CP-101,606 (10 mg/kg) and JR-220 (10 mg/kg) in DID

In screen 2, 20 mg/kg JR reduced ETOH consumption relative to saline
t(18)=9.074, p<.001. Acamprosate was associated with increased consumption,
t(18)=2.161, p=.044 (an unexpected finding, discussed in detail below). These results are
presented in Figure 30.
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Figure 30. JR-220 (20 mg/kg) and Acamprosate (300 mg/kg) in DID

DID (Screen) Summary
Results from both DID experiments indicated the abilities of CP and JR to reduce
binge-like consumption in this limited-access drinking paradigm. In the first experimental
screen, due to concerns about potential secondary effects of JR-220 (i.e., sedation), we
selected the lowest dose (10 mg/kg) of JR which demonstrated efficacy in previous
drinking screens. Due to the lack of data concerning CP-101 in ETOH consumption
paradigms, we selected a moderate dose (10 mg/kg) based on other animal studies which
demonstrated positive behavior effects (e.g., Kundrotiene et al., 2004). Both compounds
reduced consumption by a magnitude of ~50%. In the subsequent screen, a higher dose of
JR was selected in order to establish (or at least begin to provide evidence for) a dosedependent effect. While such an effect would have been interesting to examine for CP101 as well, we prioritized the examination of acamprosate in order to demonstrate the
predictive validity of the screen under our particular experimental methods. The higher
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dose of JR (20 mg/kg) reduced consumption by an even greater proportion, relative to
saline-treated animals.

Acamprosate was unexpectedly associated with increases in consumption. Exactly
what this indicates is unclear, however it should be noted that consumption following
saline injection during screen 2 was unusually low (~2.25 g/kg) compared with screen 1
(~3.25 g/kg), and may have either driven or contributed to this effect. Vehicle-associated
consumption in the DID literature resembles our screen 1 results, suggesting untreated
consumption in screen 2 was abnormally low. The nature of our screening procedure is
such that to maximize the number of compounds examined, lower subject sizes than
might otherwise be expected in more rigorous experiments, are utilized. Thus, although
not explicitly noted above, our post hoc analyses and treatment of family-wise error
throughout this project are generally liberal. While advantageous in some respects, this
increases the probability of type 1 errors. Considering this liberality, the low magnitude
of the observed effect (~.5 g/kg), the abnormality of screen 2 vehicle-associated
consumption and the inconsistency with Dr. Rhodes’ examinations of acamprosate in a
similar model, we felt drawing conclusion from this result would be premature.

While acamprosate effects in our DID screen should be investigated further,
results from Experiments 1-5 suggested that more rigorous exploration using
standardized models with larger n’s was warranted. While any numbers of well-used
models in the preclinical literature might have been selected from, DID was attractive for
two major reasons. Firstly, relative to relapse and cue-conditioning models, NMDAr
antagonism has remained largely unexplored in models of binge-like consumption, thus
DID allowed for both a pointed examination of the potential of these two compounds, as
well as an opportunity to contribute to an emerging literature. Secondly, while screening
results from JR and CP appeared quite promising, it was concerning that in our hands
acamprosate was ineffective; DID remained the only paradigm in which JR/CP results
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were inconsistent with acamprosate results, which seemed to warrant further
investigation. Both compounds were tested in the standard DID model (Experiment 8).
These results supported the hypothesis that inhibitory polyamine modulation would
reduce binge-like consumption in a limited access DID screen.
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Experiment 7: Open Field Activity
While the positive activity of both JR and CP in the screens presented here is
encouraging, one interpretational concern involved the effects of these compounds on
general activity levels. Additionally, the hypoactive effect of JR noted in the EPM, as
well as the general reduction in fluid consumption noted in ADE, raised suspicion that JR
may be altering activity. For these reasons alone, examining activity seemed prudent,
however the examination of these compounds also afforded their comparison to other
GLUergic manipulations, as well as secondary analyses of center-zone activity; entries
into the center are generally associated with reductions in anxiety and are negatively
correlated with behavioral and physiological measures of fear (Archer, 1973), however
may also evidence deficits in inhibitory control.

Open field results are presented by species, using the same order in which the
behavioral experiments are presented, including Swiss Webster mice (Experiments 2 &
3), Sprague-Dawley rats (Experiment 4) and C57BL/6J mice (Experiments 5 & 6). All
open field subjects were drug-naïve (i.e., not used in any previous experiments).

Analysis
While methods varied depending on species/strain, activity was analyzed
similarly, using RM ANOVAs (time x treatment), with either Fisher’s protected t or
Dunnett’s post hoc tests, as appropriate. Center-dwell time was analyzed with one-way
ANOVA (treatment), with Fisher’s protected t tests where appropriate.

Open Field Methods (Swiss Webster)
The activity of adult male Swiss Webster mice (30±2 g; N=20; n’s=4) was
analyzed following the administration of both CP and JR. The apparatus was a square,
black, plexiglass chamber (64 x 64 x 64 cm). Subjects were transported to a darkened
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testing room and habituated for 10 min. Each subject was then individually placed in the
open field and recorded for 10 min using a tripod-mounted video recorder (SONY). For
analysis, the open field was divided into quadrants, each comprising 25% of the total
area. Additionally, a smaller square (25% of the total area) was super-imposed over the
center of the open field. The dependent variables included number of quadrant crosses
and time spent in the center zone.

Results (Swiss Webster)
High-dose CP (20 mg/kg) was associated with hyperactivity, while high-dose JR220 induced hypoactivity. The initial RM ANOVA (time x treatment) indicated main
effects of both time F(4,60)=29.622, p<.001, and treatment, F(4,15)=10.562, p<.001. To
further examine the treatment effect, a one-way ANOVA was conducted using total
quadrant crosses over the 10-minute activity period. Again, a significant effect of
treatment was noted, F(4,19)=10.692, p<.001, with Dunnett’s tests indicating significant
increases in crosses associated with 20 mg/kg CP (p=.054) and decreases associated with
40 mg/kg JR (p=.007). These results are depicted across time (by block) in Figure 31a, as
well as summed, in Figure 31b.
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Figure 31a. Open Field Quadrant Crosses (By Block) Following Saline, JR and CP

Figure 31b. Open Field Quadrant Crosses (Total) Following Saline, JR and CP
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Finally, time spent in the 25% center zone was analyzed using a one-way
ANOVA (treatment). A significant effect of treatment was noted F(4,19)=5.594, p=.006.
Dunnett’s tests indicated this effect was driven by increased center dwell-time of 20
mg/kg CP-treated animals (p=.032). Time spent in the center zone is depicted in Figure
32, below.

Figure 32. Open Field Center Dwell-Time Following Saline, JR and CP

Open Field Methods (Sprague-Dawley)
The activity of (PND45) male Sprague-Dawley rats (N=18) was analyzed
following administration of JR-220. The apparatus was a circular chamber (36 cm height;
58 cm diameter) designed to prevent thigmotaxis or excessive time in corners. Subjects
were injected with IP Saline, 10 or 20 mg/kg JR 30 min prior to activity testing. 10 min
prior to testing, subjects were habituated to the darkened test room. Each subject was then
individually placed in the open field and recorded for 30 min using a video tracking
system (SMART program; Panlab, S.L.). Due to anecdotal observation that acute
sedative effects of JR were transient, an additional 30 min session was performed,
beginning 3 hours following the completion of the first session (4-4.5 hr following JR
injection). For analysis, the open field was divided into center and outer zones,
104

comprising 25% and 75% of the total area, respectively. The dependent variables
included distance traveled (in 5 min blocks) and the ratio of activity in the center vs. total
area of the field.

Results (Sprague-Dawley)
20 mg/kg JR was associated with reductions in activity. An initial RM ANOVA
for the first 30-min activity session indicated an interaction of treatment and time,
F(2,15)=4.252, p=.034, as well as a main effect of JR treatment, F(2,15)=4.055, p=.039,
thus individual one-way ANOVAs (treatment) were performed for each 5 min block.
Significant effects of treatment were noted during block 1, F(2,17)=4.731, p=.026; 3
F(2,17)=4.669 p=.027; and 4 F(2,17)=6.128, p=.003. During block 1 Fisher’s protected t
post hoc tests indicated a significant reduction in activity associated with 20 mg/kg JR
treatment, relative to saline (p=.008). During block 3, the 20 mg/kg dose reduced activity
relative to saline (p=.011) as well as the 10 mg/kg treatment (p=.038). Finally, during
block 4 the 20 mg/kg dose reduced activity relative to saline treatment, only (p=.003).
These results are depicted in Figure 33. ANOVA performed for center activity failed to
reveal any significant effect of treatment.
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Figure 33. Activity 30-60 min Following JR-220 Administration(Sprague Dawleys)

At four hours post-injection, activity reductions in 20 mg/kg JR-treated animals
remained apparent. An initial RM ANOVA for the second 30-min activity session
indicated an interaction of treatment and time, F(2,15)=9.112, p=.003, as well as a main
effect of JR treatment, F(2,15)=3.748, p=.048, thus individual one-way ANOVAs
(treatment) were performed for each 5 min block. Significant effects of treatment were
noted during blocks 1 [F(2,17)=10.650, p=.001], and 2 [F(2,17)=5.129, p=.019]. During
block 1 post hoc tests indicated the 20 mg/kg dose reduced activity relative to saline
(p=.001) as well as the 10 mg/kg treatment (p=.001). During block 2 significant activity
reductions were again noted for 20 mg/kg JR-treated animals, relative to both saline
(p=.039) and 10 mg/kg (p=.007) treatment. These results are depicted in Figure 34.
ANOVA performed for center activity failed to reveal any significant effect of treatment.
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Figure 34. Activity 4-4.5 hr Following JR-220 Administration (Sprague Dawleys)

Open Field Methods (C57BL/6J)
The activity of male C57 mice (30±2 g) was analyzed following the
administration of both CP and JR. Nineteen male C57 mice (30±2 grams) were
administered 0, 5, 10 or 20 mg/kg CP-101,606 (n’s=4-5/group). In a separate experiment,
24 additional C57s were administered 0, 10, 20 or 30 mg/kg JR-220 (n’s=6/group).
Otherwise, methods were exactly as described for Swiss Webster testing, above.

Results (C57BL/6J)
An RM ANOVA (time x treatment) conducted on CP-treated animals yielded
neither a main effect of, nor interaction with, treatment. As conducted previously, a oneway ANOVA (treatment) using total quadrant crosses similarly failed to detect any effect
107

of CP treatment. Quadrant crossings by block are depicted in Figure 35, below. No
difference in center dwell-time was detected between treatment conditions.

Figure 35. Open Field Quadrant Crosses Following Saline or CP(C57 Mice)

The highest dose of JR (30 mg/kg) was associated with marked reductions in
activity. A RM ANOVA (time x treatment) conducted on JR-treated animals indicated
both a time by treatment interaction, F(12,80)=3.700, p<.001, and a main effect of
treatment F(3,20)=23.635, p<.001. To further examine these effects, one-way ANOVAs
(treatment) were conducted for each block, individually. Significant treatment effects for
block 1, F(3,23)=12.852, p<.001, block 2, F(3,23)=15.292, p<.001 and block 3,
F(3,23)=60.056, p<.001 were noted, such that 30 mg/kg JR reduced activity relative to all
other groups (all p’s<.001). The same effect was noted for block 4, F(3,23)=4.159,
p=.019, wherein 30 mg/kg reduced activity compared to saline (p=.015), 10 (p=.006) and
20 mg/kg (p=.010), and block 5 F(3,23)=8.516, p=.001, wherein 30 mg/kg reduced
activity compared to saline (p<.001), 10 (p=.009) and 20 mg/kg JR (p=.001).
Additionally, a one-way ANOVA (treatment) was conducted using total quadrant crosses
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as the dependent variable. Again, a significant effect of treatment was detected,
F(3,23)=23.748, p<.001, such that 30 mg/kg JR-treated animals were hypoactive
compared to all others (all p’s<.001). These results are depicted across time in Figure 36,
and summed in Figure 37, below. No difference in center dwell-time was detected
between treatment conditions.

Figure 36. Open Field Quadrant Crosses Following Saline or JR (C57 Mice)
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Figure 37. Open Field Quadrant Crosses (Total) Following Saline, 10, 20 or 30 mg/kg
JR (C57 Mice)

Open Field Summary
This final experiment was somewhat atypical compared with those preceding it;
while it can be considered a screen, its main purpose was to facilitate interpretation of
experiments 1-6. Taken together, the activity data presented above indicate that while JR
and CP are both capable of behavioral disruption at higher doses (including doses
analyzed in previous experiments), several lower doses which tested positively
throughout the screening procedure showed no evidence of such disruption.

The first open field analysis included Swiss Webster mice, and was designed to
analyze the highest and lowest doses of JR and CP which demonstrated efficacy in the
behavioral experiments (10 and 40 mg/kg and 1 and 20 mg/kg doses, respectively).
Importantly, at doses which significantly reduced seizure behaviors, CP and JR-treated
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animals were indistinguishable from controls. However, an interesting difference
emerged at the high doses. 40 mg/kg JR was associated with an approximate decrease in
activity of 60%, while 20 mg/kg CP was associated with an approximately 40% increase.

The second open field analysis included Sprague-Dawley rats, and analyzed only
JR-220, and examined doses used in the ADE experiment. Anecdotally, JR appeared to
induce transient sedation in our Sprague-Dawley rats, however observable in-cage
evidence of sedation disappeared quickly. Therefore in addition to analyzing initial (and
possibly transient) alterations in activity, 30 min following administration, we re-tested
the animals 4.5 h following administration. Results were remarkably similar across
testing periods. The 10 mg/kg dose produced activity which was indistinguishable from
controls; while the 20 mg/kg dose appeared to reduce activity at both time points,
producing nearly identical patterns/magnitudes of activity. While activity was certainly
reduced among 20 mg/kg animals, it should be noted that animals remained active
throughout both 30 min testing periods, traveling similar distances as the 10 mg/kg and
saline groups during the last 10 min of the initial test and last 20 min of the final test,
suggesting the sedation was mild. Importantly, the 10 mg/kg dose reduced relapse-like
behavior, was not associated with reductions in water consumption and did not induce
hypoactive behaviors, either initially or several hours post-injection.

The final open field analysis included C57 mice, and the full range of JR doses
examined in the restraint stress and DID experiments: 10, 20 and 30 mg/kg doses.
Additionally, CP was analyzed in 5, 10 and 20 mg/kg doses. While only the 10 mg/kg
dose was analyzed in experiment 6, this dose ranged was analyzed in anticipation of a
more thorough DID analysis (described below). While activity among saline and CPtreated animals was statistically indistinguishable, the lack of an effect was likely due to
high variance and relatively low power. The trend toward higher activity among animals
receiving 10 and/or 20 mg/kg doses was consistent with the observed increase in activity
displayed by Swiss Webster mice. At the two lower JR doses examined (10 and 20
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mg/kg), no evidence of activity disturbance was observed, however the 30 mg/kg dose
was associated with a substantial reduction in activity. Unlike activity data generated in
rats, the observed activity deficit persisted across all blocks.

While the additional examination of potential anxiolytic actions of these drugs
was an advantage of including an open-field assessment, alterations in center-zone
activity were only evident in the Swiss Webster mice, and the pattern of center-zone
activity was nearly identical to the general pattern of activity, likely suggesting that
periods of immobility in these animals largely occurred in the more protected periphery.
While it is possible that center-zone patterns reflected actions on anxiety-related
behaviors, the interpretation would include anxiogenic actions of JR-220, which is
inconsistent with the examinations of compounds thought to have similar mechanisms of
action (including CP-101).
Taken together these results suggest that neither JR nor CP disrupt activity at lower
doses, but each is associated with disruption at higher doses, albeit in opposing
directions.
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Experiment 8: Drinking in the Dark (Model)
The medications development project, of which this dissertation represents only a
fraction, was specifically designed for the screening of novel compounds, with the
intention that “hits” would be subjected to a further testing with more established models,
using more rigorous methodology, more appropriate controls and/or greater n’s.
Experiment 8 was designed and included in this dissertation as the first, albeit modest,
step toward such testing. The DID model was specifically selected as the first postscreening experiment for several reasons. The paucity of NMDAr-associated
manipulations in the paradigm suggested a gap in the literature, allowing this experiment
both to advance our compounds of interest (potentially) as well as contribute to the
rapidly growing base of DID knowledge. Furthermore, since acamprosate has
demonstrated efficacy under standardized DID conditions (Gupta et al., 2008), the model
appears to possess predictive validity which was notably lacking from our initial DID
screens. Experiment 8 analyzed a range of doses for both compounds, and adhered more
rigidly to established DID methodologies.

DID (Model) Subjects
Mice (n=28; Jackson Laboratory, Bar Harbor, ME) arrived at 15 wks of age, and
were left undisturbed for 7 days prior to testing. A reverse light:dark cycle was again
employed, with lights turned on at 2100 h and off at 900 h.

DID (Model) Procedure
Animals were habituated, housed and handled as previously detailed. Procedures
for Experiment 8 differed in that only one week (4 days, total) of ETOH access was given
prior to the first week of treatments. Additionally, the treatment schedule was varied,
however as in Experiment 6, all animals received all doses of each compounds, in a
within-subjects, latin-square design (see Figures 38 & 39). Finally, a 3 hr delay (Rhodes
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et al., 2005) between ETOH access and initiation of the dark cycle was used (vs. 4 hr in
screening).
Figure 38. Latin-Square Treatment Design (Weeks 1-2: 0, 5, 10, 20 mg/kg CP;
Weeks 3-4: 0, 5, 10, 20 mg/kg JR)

Pre-treatment Drinking: The water bottles were replaced with cylinders containing 20%
ethanol, which remained undisturbed for 4 hours, after which consumption was recorded
and water bottles returned. Habituation lasted for one week (4 days of ETOH access).
Week 1 & 2: Methods were identical to habituation drinking, with the addition of
injections (0, 5, 10, 20 mg/kg, ip) of CP-101,606 on treatment days, given immediately
prior to ETOH access.
Week 3 & 4: Methods were identical to habituation drinking, with the addition of
injections (0, 5, 10, 20 mg/kg, ip) of JR-220 on treatment days, given immediately prior
to ETOH access.
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Figure 39. DID ETOH Access Schedule (Single Drug Treatment; Dark/Light Boxes
Indicate ETOH/Water, Respectively)

DID (Model) Results
CP significantly reduced ETOH intake, F(1,27)=59.627, p<.001. Paired-samples
t-tests revealed all doses differed from saline, including 5 t(27)=3.243, p=.003, 10,
t(27)=7.444, p<.001, and 20 mg/kg, t(27)=6.065, p<.001. These results are depicted in
Figure 40.
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Figure 40. Ethanol Consumption Following CP-101,606 Administration

JR significantly reduced ETOH intake, F(1,26)=232.346, p<.001. Paired-samples
t-tests revealed all doses differed from saline, including 5 t(26)=6.206, p=.001, 10,
t(26)=8.986, p<.001, and 20 mg/kg, t(26)=16.103, p<.001. These results are depicted in
Figure 41.
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Figure 41. Ethanol Consumption Following JR-220 Administration

DID (Model) Discussion
Results of this experiment were consistent with screening results; CP appeared to
reduce consumption relative to vehicle at all doses, however, these reductions did not
appear dose-dependent. JR also reduced consumption, however, consistent with the
screening results, such reduction appeared dose-dependent, with the 20 mg/kg dose
drastically reducing intake. These results are also consistent with the observations of
Rhodes and colleagues (Rhodes, personal communication), who examined JR-220 at
these doses as well, however this group observed significant reductions in ETOH
consumption only at the highest (20 mg/kg) dose.
The relevance of these results is supported by the relatively recent recognition of
DID as a powerful preclinical tool for medications development, with a number of
promising compounds having recently demonstrated reduction in binge-like intake,
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including baclofen, CRF antagonists, mGLUr antagonists, mecamylamine and lobeline
(Moore & Boehm, 2009; Sajja & Rahman, 2011; Gupta et al., 2008; Hendrickson, ZhaoShea & Tapper, 2009; Sparta et al., 2008). While somewhat surprising that NMDAr
compounds have remained unexamined, our results serve the dual-purpose of advancing
the development of CP and JR, as well as further implicating the role of glutamate (in
general), NMDAr (in particular) and polyamine-sensitive receptor subtypes (specifically)
in binge-like intake, a behavior which they are not well-recognized for.

Copyright © Ben Lewis 2011
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Chapter 8. General Discussion
8.1 Summary of Results
Current evidence suggests that JR-220 and CP-101,606 (Haradahira et al., 2002;
Mott et al., 1998) are both inhibitory modulators of the NMDAr, whose mechanisms of
action involve interference with polyamine binding. Thus, for numerous reasons
discussed above, it was hypothesized that both would perform positively in screens
designed to examine withdrawal symptoms, neurotoxicity, ETOH reinforcement, relapse
behavior, stress-associated drinking and ETOH-associated cue conditioning (see Figure
XX, below). Furthermore, based on success in these screens, efficacy in a standardized
DID model was hypothesized. Our results were consistent with these hypotheses, despite
the recognitions that CP needs to be examined in additional screens (e.g., ADE) and that
some findings deserve more thorough re-examination (e.g., reductions in stretched-attend
posture).
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Figure 42. Model of Drinking Progression With Experimental Evidence for
Intervention

Our results suggested that both JR and CP possess neuroprotective potential in an
in vitro screen using organotypic hippocampal slices withdrawn from ETOH. Consistent
with this demonstration of in vitro neuroprotection, our behavioral HIC screen
demonstrated the ability of these compounds to reduce withdrawal-associated convulsive
behaviors, which are associated with underlying excitotoxic insult and index withdrawal
severity. Taken together with molecular screens conducted previous to this dissertation,
and with the results of behavioral data from neonatal studies which used JR and CP as
neuroprotective interventions during developmental ETOH exposure (Lewis et al.,
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submitted; Wellmann et al., in press), evidence for the neuroprotective potential of both
compounds is strong.
Our EPM screen suggested JR’s ability to reduce ETOH-associated cue
conditioning, although these data should be interpreted carefully, given the potential
hypoactive and/or anxiolytic effects of JR in this paradigm. Results from the ADE screen
indicated anti-relapse efficacy. Our restraint-stress screen demonstrated JR’s ability to
reduce ETOH’s negative reinforcing value, while our DID experiments suggested the
ability to reduce its positive reinforcing value. Taken together, these results suggest JR’s
ability to reduce multiple motivational factors contributing to relapse. While full
screening of CP was not possible, its similar mechanism of action, similar action in HIC
screening, and positive performance in all DID experiments suggests that it too possesses
strong potential, however more thorough screening is required. Taken together, the
performance of these compounds in our screening procedure provides strong evidence
for both drugs as potential pharmacotherapeutics for alcoholism, and further implicate
polyamines and NR2B subunits in multiple mechanisms of ETOH consumption and
withdrawal.

Although these two drugs are thought to have similar mechanisms of action, albeit
in variable receptor populations, dissociations in their performance were particularly
interesting. For instance, CP-101 appeared far more potent in the screens for
neuroprotective potential (OHSC and HICs). Current evidence suggests that NR2B/2Bcontaining receptors represent a high-risk subpopulation that is particularly sensitive to
such insults. However, at equal doses CP’s performance was not distinguishable from
JR’s in the DID paradigm, suggesting that while NR2B/2B subpopulations appear to
contribute to this type of drinking behavior, their contribution is shared. A particularly
interesting, if somewhat puzzling, dissociation in the behavioral effects of these
compounds involves the bidirectionality of their effects on activity. CP appears to
increase open-field activity, while JR-220 appears to reduce it. This difference may be
indicative of the differential contributions of NR2B-containing subpopulations to activity.
It is possible that antagonism of NR2B/2B stimulates motor activity, while antagonism of
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a more heterogenous receptor population depresses it. While supported by the
observation that nonspecific antagonism depresses activity (Ghasemi et al., 2010) the
lack of clear indication in the literature as to ifenprodil/eliprodil effects on open field
activity makes this interpretation tentative, at best. An alternate interpretation would
suggest that one or both compounds may be interacting with unknown and unanticipated
transmitter systems, the resulting in disrupted activity. Regardless, such differences
illustrate the clear need for further investigation of both compounds.

8.2 Clinical Futures
This dissertation has used our group’s screening procedure as a hypothesis-testing
device. Although the screens provide useful data which allows for the constant reevaluation and alteration of our underlying hypotheses, their primary utility is the
discovery and development of novel compounds for eventual clinical use. However, even
perfect performance throughout the screening hierarchy cannot be taken as evidence of
the compounds’ ability to clear any of the numerous hurdles involved with progression
from ‘bench to bedside’. While not the focus of this dissertation, potential future
difficulties in the advancement of JR-220 (and similar agmatine analogues) are worth
consideration, and may guide future studies.

Recent estimates suggest that for every one compound receiving FDA approval,
approximately 10,000 molecules are synthesized in drug discovery programs. Of these
10,000, roughly 2.5% will advance to preclinical testing and only .05% to Phase I trials.
That said, it must be noted that while JR-220’s influence on ETOH intake behavior is
marked, little more than gross toxicity analyses have been performed; none of the
numerous toxicology screens (e.g., genotoxicity, hemolysis, cardiotoxicity, mitochondrial
toxicity, reactive metabolite screening, etc.) have been conducted, nor have any ‘ADME’
(absorption, distribution, metabolism and excretion) screens. Our application to the NIH
Rapid Access to Interventional Development (RAID) program, if accepted, will begin
such examination. If JR-220 survives the significant failure rate associated with such
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toxicological/kinetic measures and advances to Phase I testing, its chances remain low:
CNS drugs have a historically low success rate, with roughly 7.5% of Phase 1 trials
producing marketable compounds. While JR-220 has several advantages which may
increase these odds, including its similarity to an endogenous molecule (agmatine), and
its modulatory action at the target (thought to be a self-limiting characteristic in terms of
toxicity) its chances of advancement to bedside are limited. An objective acceptance of
the sizeable odds against JR-220’s success is useful to avoid the recognized pitfall of
“championing” a promising compound which represents a significant amount of invested
time and money, past the point at which evidence suggests its limited utility. However the
recognition of such sizeable odds should not be taken as reluctance or reservation to
continue JR-220’s investigation. Unlike other areas of drug discovery, many of which
have existing pharmacotherapies with acceptable effectiveness, the success of current
FDA-approved medications for treating alcohol related disorders has been marginal, at
best. When considered alongside the number of people affected by alcohol dependence
issues, the ‘big risk/big reward’ assessment of medications development work in this
field becomes apparent. Thus, despite probable failure, the cost-benefit analysis of
continuing to invest in JR-220 and in future medications development endeavors of this
nature seems clear.

In contrast with JR, CP has already surmounted many of the challenges involved
in progressing to humans. CP is orally bioavailable (Taylor et al., 2006), and appears
well-tolerated, with a favorable side-effect profile. However, clinical trials for several
(non ETOH-related) diseases have revealed only modest effects. A clinical TBI study
indicated outcome improvements and reductions in mortality rates, however effects were
only marginally significant (p’s = .07 and .08, respectively; Yurkewicz et al., 2005). A
clinical Parkinson’s study found CP was effective at reducing levodopa-induced
dyskinesia effects, but not Parkinsonism itself (Nutt et al., 2008). Interestingly, it appears
to produce antidepressant effects in patients unresponsive to serotonin selective reuptake
inhibitors (Skolnick et al., 2009). However, interest in the compound appears to be
decreasing; pubmed searches indicated 15 publications related to CP during 2004-2005
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(at the time when our group noted the compound and began examining it in FASD
experiments), however only 5 five were noted from 2010 to the current date, all of which
utilize it as a pharmacological tool in preclinical examinations. Such loss of interest may
reflect clinical shortcomings of CP, but may also be related to the recognition that CP
shares discriminative stimuli with phencyclidine; it is self-administered in non-human
primates who were experienced with PCP administration (Nicholson et al., 2007),
consistent with observations that CP is dose-dependently associated with dissociative and
amnestic effects (Nutt et al., 2008).

The current work is focused specifically on alcoholism and alcohol-related
effects, however, as the aforementioned investigations of CP indicate, NMDAr
modulators are implicated as potential pharmacotherapeutics for a startlingly large
number of conditions, including chronic pain, Huntington’s, Parkinson’s, migraine, major
depression, stroke/ischemic injury, epilepsy, and others. While speculative, it is not
unlikely that in the discovery and development of inhibitory modulators for alcohol
dependence, compounds with utility in some, if not many, of these additional disorders
may be produced. An alternate future for these compounds, mentioned only briefly in the
introduction, involves neuroprotection from ETOH insult in utero, and in particular, from
the prolonged withdrawal following birth. No pharmacotherapeutic intervention is
currently available for FASDs, which are thought to involve similar if not identical
excitotoxic mechanisms as those presented here, providing yet another potential avenue
of JR-220 development.

Though not explicitly stated thus far, one potential contribution of the current
work may not include either compound, but rather the demonstration of this type of
project’s utility. JR’s transition from simple molecular screening to success in a strong
preclinical model (the majority of which is contained herein) provides evidence that a
small research team can accomplish this type of directed drug discovery and
development. Furthermore, our inclusion of CP in various screens demonstrates the
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flexibility of the program, which allows for both ‘bottom-up’ examination of novel
compounds, as well as ‘top-down’ testing of known compounds.

Finally, while this dissertation represents only one of the first few steps toward
the potential clinical development of these compounds, our results provide strong
evidence for both drugs as potential pharmacotherapies, further implicate polyamines and
NR2B subunits as critical mechanisms in ETOH consumption and withdrawal and
demonstrate the utility of academic drug discovery and development programs.

Copyright © Ben Lewis 2011
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Appendix A: Table Legend

Table 1. Species/Strain Use by Experiment
Table 2. JR-220 Treatments & Subjects
Experiments with JR utilized six litters (N=217), distributed across 20 treatment groups. These included
Control (n=23), ETOH (n=22), Control + 20N (n=18), ETOH + 20n (n=19), Control + MK (n=18), ETOH
+ MK (n=20), Control + 50 μM JR (n=8), Control + 60 μM JR (n=7), Control + 75 μM JR (n=16), Control
+ 80 μM JR (n=4), Control + 90 μM JR (n=3) Control + 100 μM JR (n=4), Control + 125 μM JR (n=4),
ETOH + 50 μM JR (n=7), ETOH + 60 μM JR (n=8), ETOH + 75 μM JR (n=18), ETOH + 80 μM JR (n=3),
ETOH + 90 μM JR (n=4), ETOH + 100 μM JR (n=4) and ETOH + 125 μM JR (n=6).
Table 3. CP-101 Treatments & Subjects
Experiments with CP utilized five litters (N=177), distributed across 16 treatment groups. These included
Control (n=21), ETOH (n=21), Control + 20N (n=12), ETOH + 20N (n=12), Control + MK (n=12), ETOH
+ MK (n=12), Control + 5 nM CP (n=6), Control + 10 nM CP (n=10), Control + 25 nM CP (n=12), Control
+ 50 nM CP (n=12), Control + 75 nM CP (n=4), ETOH + 5 nM CP (n=6), ETOH + 10 nM CP (n=9),
ETOH + 25 nM CP (n=12), ETOH + 50 nM CP (n=12) and ETOH + 75 nM CP (n=4).
Table 4. Handling-Induced Convulsion Assessment Scale
Adapted/modified from Wilson & Little, 1998.
Table 5. Sucrose Fading Schedule
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Appendix B: Figure Legend

Figure 1. Simplified Polyamine Biosynthesis (adapted from Coffino, 2001)
Figure 2. Contributions of ETOH Withdrawal to Reinforcement and Cue Salience
Figure 3. Molecular Structure of Ifenprodil and its Analogue, CP-101,606
Figure 4. Molecular Structure of Agmatine and its Analogue, JR-220
Figure 5. Treatment Distribution Within a Single Culture
Figure 6. JR-220 in CA1
PI florescence, by group mean + S.E.M, in CA1 of organotypic hippocampal slice cultures. Data collapsed
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. *
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOHnaïve control group.
Figure 7. JR-220 in CA3
PI florescence, by group mean + S.E.M, in CA3 of organotypic hippocampal slice cultures. Data collapsed
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. *
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOHnaïve control group.
Figure 8. JR-220 in DG
PI florescence, by group mean + S.E.M, in DG of organotypic hippocampal slice cultures. Data collapsed
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. *
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOHnaïve control group.
Figure 9. CP-101,606 in CA1
PI florescence, by group mean + S.E.M, in CA1 of organotypic hippocampal slice cultures. Data collapsed
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence. *
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOHnaïve control group.
Figure 10. CP-101 in CA3
PI florescence, by group mean + S.E.M, in CA3 of organotypic hippocampal slice cultures. Data collapsed
across sex and converted to % control. Horizontal black line indicates 100% control fluorescence *
indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOHnaïve control group.
Figure 11. CP-101 in DG
PI florescence, by group mean (+S.E.M.), in CA3 of organotypic hippocampal slice cultures. Data
collapsed across sex and converted to % control. Horizontal black line indicates 100% control fluorescence.
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* indicates significance (p<.05) relative to ETOH control group; # indicates significance relative to ETOHnaïve control group.
Figure 12. Representative Slices From Select Treatment Groups
Including Control (a), ETOH (b), 20 μM NMDA (c), 50 μM JR-220 (d), 25 nM CP-101 (e), and 20 μM
MK-801 (f).
Figure 13. BEC as a Function of Time and 4MP Treatment
Blood ethanol content, presented as mean (±S.E.M.) mg/dl, following 2.5 g/kg ETOH administration.
Groups included 4MP (9 mg/kg) and control. * indicates significance (p<.05) between groups.
Figure 14. JR-220 HICs, Percent Control Values
Handling Induced Convulsion scores, presented as mean (+S.E.M.) percentage of ETOH-naïve scores. *
indicates significance (p<.05) relative to drug-naïve (0 mg/kg) group.
Figure 15. CP-101,606 in HICs, Percant Control Values
Handling Induced Convulsion scores, presented as mean (+S.E.M.) percentage of ETOH-naïve scores. *
indicates significance (p<.05) relative to drug-naïve (0 mg/kg) group.
Figure 16. Stretched-Attend Behaviors
Stretched-attend postures, presented as mean (+S.E.M.). Groups included ETOH-treated and ETOH-naïve
animals, treatments included saline and 20 mg/kg JR-220. * indicates significance (p<.05) between
treatment conditions.
Figure 17. Time Spent in Closed vs. Open arms
Time in open and closed arms, respectively, presented by as mean (+S.E.M.) seconds. Groups included
ETOH-treated and ETOH-naïve animals, treatments included saline and 20 mg/kg JR-220. * indicates
significance (p<.05) between treatment conditions.
Figure 18. Total Arm Entries
Arm entries (open and closed), presented as mean (+S.E.M.) entries. Groups included ETOH-treated and
ETOH-naïve animals, treatments included saline and 20 mg/kg JR-220. * indicates significance (p<.05)
between treatment conditions.
Figure 19. 20 mg/kg JR in ADE
ETOH consumption during baseline, untreated ADE period, and treated ADE period. Presented as daily
mean (+S.E.M.) g/kg. Treatments included vehicle and 20 mg/kg JR-220. * indicates significance (p<.05)
relative to baseline consumption.
Figure 20. Water consumption in ADE reinstatement phases (20 mg/kg)
Water consumption during baseline, untreated ADE period, and treated ADE period. Presented as daily
mean (+S.E.M.) g/kg. Treatments included vehicle and 20 mg/kg JR-220. * indicates significance (p<.05)
relative to baseline consumption.
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Figure 21. 10 mg/kg JR-220 in ADE
ETOH consumption during baseline, untreated ADE period, and treated ADE period. Presented as daily
mean (+S.E.M.) g/kg. Treatments included vehicle and 10 mg/kg JR-220. * indicates significance (p<.05)
relative to baseline consumption.
Figure 22. Water Consumption during ADE reinstatement phases (10 mg/kg)
Water consumption during baseline, untreated ADE period, and treated ADE period. Presented as daily
mean (+S.E.M.) g/kg. Treatments included vehicle and 10 mg/kg JR-220. * indicates significance (p<.05)
relative to baseline consumption.
Figure 23. Restrained vs. Unrestrained Drinking
ETOH consumption, presented as mean (±S.E.M.) g/kg. Treatments included restraint-stress and control
handling. * indicates significance (p<.05) between treatments.
Figure 24. JR-220 Treatment (Following 5-day Restraint Period)
ETOH consumption among restrained animals, presented as mean (+S.E.M.) g/kg. Treatments included 0,
10, 20 and 30 mg/kg JR-220. * indicates significantly (p<.05) increased consumption relative to all other
groups. # indicates significantly (p<.05) reduced consumption relative to all other groups.
Figure 25. Unrestrained Animals, 0 vs. 30 mg/kg JR
ETOH consumption among unrestrained animals, presented as mean (±S.E.M.) g/kg. Treatments included 0
and 30 mg/kg JR-220.
Figure 26. Latin-Square Design for Screen 1 and Screen 2
Screen 1: Saline, 10 mg/kg CP, 10 mg/kg JR; Screen 2: Saline, 20 mg/kg JR, 300 mg/kg Acamprosate
Figure 27. DID ETOH Access Schedule
Figure 28. Daily DID Consumption (4hr/day) Prior to Treatment Phase
ETOH consumption during the last three weeks of untreated 4 hr consumption, presented as mean
(±S.E.M.) g/kg ETOH consumption.
Figure 29. CP-101,606 (10 mg/kg) and JR-220 (10 mg/kg) in DID
ETOH consumption during the first DID treatment phase, presented as mean (+S.E.M.) g/kg ETOH
consumption. Treatments included CP-101 (10 mg/kg), JR-220 (10 mg/kg), and saline. * indicates
significant (p<.05) difference from vehicle treated drinking.
Figure 30. JR-220 (20 mg/kg) and Acamprosate (300 mg/kg) in DID
ETOH consumption during the second DID treatment phase, presented as mean (+S.E.M.) g/kg ETOH
consumption. Treatments included JR-220 (20 mg/kg), acamprosate (300 mg/kg) and saline. * indicates
significant (p<.05) difference from vehicle treated drinking.
Figure 31a. Open Field Quadrant Crosses (By Block) Following Saline, JR and CP
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Open field activity among Swiss Webster mice, presented as presented as mean (±S.E.M.) quadrant
crosses, per 2 min block. Groups includes JR-220 (10 and 40 mg/kg), CP-101 (1 and 20 mg/kg) and saline.
Figure 31b. Open Field Quadrant Crosses (Total) Following Saline, JR and CP
Open field activity among Swiss Webster mice, presented as presented as mean (±S.E.M.) total quadrant
crosses. Groups includes JR-220 (10 and 40 mg/kg), CP-101 (1 and 20 mg/kg) and saline. * indicates
significant (p<.05) difference relative to saline control.
Figure 32. Open Field Center Dwell-Time Following Saline, JR and CP Treatment
Center zone activity among Swiss Webster mice, presented as mean (+S.E.M.) time spent (sec). Groups
includes JR-220 (10 and 40 mg/kg), CP-101 (1 and 20 mg/kg) and saline. * indicates significant (p<.05)
difference relative to saline control.
Figure 33. Activity 30-60 min Following JR-220 Administration (Sprague Dawleys)
Open field activity among Sprague-Dawley rats, recorded 30 min following drug administration, presented
as mean (±S.E.M.) distance (cm) in 5 min bins. Treatments included JR-220 (10 and 20 mg/kg) and saline.
*indicates significant (p<.05) treatment effect, such that activity differed between saline and 20 mg/kg
treated animals.
Figure 34. Activity 4-4.5 hr Following JR-220 Administration (Sprague Dawleys)
Open field activity among Sprague-Dawley rats, recorded 4 hr following drug administration, presented as
mean (±S.E.M.) distance (cm) in 5 min bins. Treatments included JR-220 (10 and 20 mg/kg) and saline.
*indicates significant (p<.05) treatment effect, such that activity differed between saline and 20 mg/kg
treated animals.
Figure 35. Open Field Quadrant Crosses Following Saline or CP (C57 Mice)
Open field activity among C57BL/6J mice, presented as mean (±S.E.M.) quadrant crosses in 2 min bins.
Treatments include 0, 5, 10 or 20 mg/kg CP-101.
Figure 36. Open Field Quadrant Crosses Following Saline or JR (C57 Mice)
Open field activity among C57BL/6J mice, presented as mean (±S.E.M.) quadrant crosses in 2 min bins.
Treatments include 0, 10, 20 or 30 mg/kg JR-220. * indicates significance (p<.05) relative to saline control.
Figure 37. Open Field Quadrant Crosses (Total) Following Saline, 10, 20, or 30 mg/kg JR
Open field activity among C57BL/6 mice, presented as presented as mean (±S.E.M.) total quadrant
crosses. Groups includes 0, 10, 20 and 30 mg/kg doses of JR-220. * indicates a significant (p<.05)
difference relative to all other groups.
Figure 38. Latin Square Treatment Design
Weeks 1-2: 0, 5, 10, 20 mg/kg CP; Weeks 3-4: 0, 5, 10, 20 mg/kg JR
Figure 39. DID ETOH Access Schedule
Figure 40. Ethanol Consumption Following CP-101,606 Administrationin
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ETOH consumption during the first DID treatment phase, presented as mean (+S.E.M.) ETOH
consumption (mL), following injections of 0, 5, 10, and 20 mg/kg CP-101,606. * indicates significant
(p<.05) difference from vehicle treated drinking.
Figure 41. Ethanol Consumption Following JR-220 Administration
ETOH consumption during the first DID treatment phase, presented as mean (+S.E.M.) ETOH
consumption (mL), following injections of 0, 5, 10, and 20 mg/kg JR-220. * indicates significant (p<.05)
difference from vehicle treated drinking.
Figure 42. Model of Relapse Progression with Experimental Evidence for Intervention
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